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ABSTRACT 
CONTRIBUTION OF NOTCH SIGNALING ON HCC STEM CELL STATUS 
AND UTILIZING TLR AGONISTS AND NOTCH INHIBITION TO IMPROVE 
HCC THERAPY 
Yusuf İsmail ERTUNA 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Prof. Dr.  İhsan Gürsel  
Co–Supervisor: Prof. Dr. Mehmet Öztürk 
September 2014, 113 Pages 
Hepatocellular carcinoma (HCC) is the seventh most common cancer type 
worldwide, and ranked third place among cancer-related deaths within both sexes.  
As in many solid tumors, HCC shelters a cancer stem cell subpopulation, and is held 
responsible for the resistance developed during chemo-and-radio-therapy of HCC. 
The only option to cure HCC is liver transplantation, which is the bottleneck to 
provide a remedy to patients due to limited availability. Understanding the stem cell 
behavior of HCC would critically contribute to develop effective eradication 
strategies. In this study, a panel of 17 HCC cell lines was evaluated for their CSC 
status. Of these cell lines, six of them were determined to be positive for CD133 
expression, a cardinal CSC marker. Next, HepG2, Huh7 and Hep3B-TR, (a 
desensitized TGF-beta-1 receptor clone) were selected and Notch activity vs. CSC 
fraction was investigated by analyzing CD133+/EpCAM+ levels. Our results 
revealed that DAPT (a notch inhibitor) led to a drop in CD133+/EpCAM+ levels in 
HepG2 and Huh7 by half, but not in Hep3B-TR cells, implicating a possible 
TGFβ1R involvement on CSC generation/maintenance. Treatment of cells with a 
notch ligand, Jagged-1, however, had little or no positive effect on 
CD133+/EpCAM+ expressions in all tested cells. Additionally,  HCC cells' response 
to different TLR ligands and the resulting transcript expressions of TLRs were 
investigated by PCR. Of note, TLRs are widely used in immunotherapy of cancers. 
Here we aimed to combine Notch inhibitor along with selected TLR ligand, thereby 
improving tumor clearance in athymic mice xenografted with HCC. We found that in 
three selected cell lines upon TLR2 ligand stimulation, TLR5 and TLR7 were highly 
upregulated. Afterwards, treating these HCC cell lines with these ligands we 
observed that TLR3, TLR7/8 and TLR9 levels were activated. In the final part of this 
study, tumor-bearing mice with Huh7, were subjected to a combination therapy with 
TLR ligands +/- DAPT.  We demonstrated that combination therapy comprising 
TLR3, 7/8 and 9 ligands and DAPT (only two injections, a week apart) induced 
significant tumor regression.  
Keywords: Hepatocellular carcinoma, Cancer stem cells, Notch signaling pathway, 
Toll-like receptors, CD133, EpCAM, Therapy. 
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ÖZET 
NOTCH YOLAĞININ HCC KÖK HÜCRELERİNE KATKISI VE HCC TEDAVİSİ 
İÇİN TLR ULAKLARIYLA NOTCH BASKILAMASININ KULLANILMASI 
Yusuf İsmail ERTUNA 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Danışman: Prof. Dr.  İhsan Gürsel 
Eş Danışman: Prof. Dr. Mehmet Öztürk 
Eylül 2014, 113 Sayfa 
Hepatosellüler karsinom (HSK) dünya genelinde en sık görülen kanserler 
sıralamasında yedinci, kanser kaynaklı ölümler göz önünde bulundurulduğunda ise 
üçüncü sırada yer almaktadır. Birçok solid tümörde görüldüğü gibi, HSK 
tümörlerinde de bir kanser kök hücresi altpopulasyonu barındırdığı bilinmektedir. Bu 
nedenle, HSK tümörlerinin radyoterapi ve kemoterapiye direnç geliştirmeleri bu 
kanser kök hücrelerinin düzeyleriyle sağlanmakta olduğu düşünülmektedir. 
Günümüzde HSK tedavisi için en etkin yol  karaciğer naklidir. Ne yazık ki, uygun 
donör azlığı bu yaklaşımın etkin sağaltım sağlamasını sınırlı kılmaktadır. Bu 
bağlamda, karaciğer kanseri kök hücre altgruplarıın düzeyini belirleyip miktarını 
azaltacak stratejiler geliştirmek, etkili tedavi yöntemleri geliştirilmesine önemli 
katkılarda bulunacaktır. Bu çalışmada, HSK kökenli 17 hücre hattı kullanılarak bir 
kanser kök hücresi paneli oluşturulmuştur. İmmünoperoksidaz ve Akım Sitometresi 
tenikleriyle gerçekleştirilen tarama sonunda altı KKH'nın kabul edilen bir kanser kök 
hücresi (KKH) markörü olan CD133 ifadesi bakımından oldukça pozitif olduğu 
saptanmıştır. Daha sonra üç hücre hattı HepG2, Huh7 ve Hep3B-TR (TGF-beta-1 
almaçı duyarsızlaştırılmış) seçilerek Notch yolağının etkinleştirilmesi veya 
bastırılması, kök hücre altgrubu düzeyine olan etkisi belirlenmiştir.. Elimizdeki 
veriler, Huh7 ve HepG2 hücre hatlarının DAPT (bir tür gamma-sekretaz inhibitörü) 
ile muamelesi sonucunda CD133+/EpCAM+ KKH altpopulasyonun yarı yarıya 
azaldığını, buna karşın Hep3B-TR hücrelerinde herhangi bir değişim saptanmadığı 
gözlenmiştir. Bu veriler, TGFβ1 reseptörünün KKH oluşumunda ve devamlılığında 
rolü olabileceği ihtimalini önermektedir. Seçilen hücre hatlarının Jagged-1 (Notch 
ligandı) ile muamelesi sonucunda ise KKH altpopulasyonu üzerine bir etki 
oluşturmamıştır. Bu hücre hatlarının bazal toll-benzeri reseptör (TLR) ifade 
düzeyleri PZR metoduyla incelendiğinde, TLR5 ve TLR7 transkriptlerinin yüksek 
olduğu bulunmuştur. Bu ulaklarla hücreleri muamele edilince de, TLR3, 7/8 ve 9 
genlerinin daha fazla arttırdığı gözlenmiştir. Bu sonuçların ışığında Notch 
inhibitörüyle, TLR ulaklarının kullanıldığı bir kombine tedavinin HSK tümörü 
geliştirilmiş atimik farede denenmesi planlanmıştır. Çalışmanın son bölümünde, 
Huh7 hücreleri farelere zenograft edilerek, ya sadece TLR ligand kokteyli, veya 
DAPT eklenmiş şekilde, iki kez  peritümöral enjeksiyonu sonunda (bir hafta arayla) 
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tümör düzeyleri takip edilmiştir. Sonuç olarak, TLR3, TLR7/8 ve TLR9 ligandlarının 
DAPT ile kombine terapisinin uygulandığı hayvanlardaki tümör boyutlarının önemli 
derecede gerilediği bulunmuştur. 
Anahtar sözcükler: Hepatosellüler karsinom, Kanser kök hücresi, Notch sinyal 
yolağı, Toll benzeri reseptör, CD133, EpCAM, Tedavi . 
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Chapter 1 
1. Introduction 
1.1 Hepatocellular carcinoma 
 
1.1.1 Epidemiology of Hepatocellular Carcinoma 
Liver cancer has a 4.6% survival rate, which renders it to be the second most lethal 
cancer type worldwide in both sexes after pancreas cancer 
1
. The severity of liver 
cancer stems from several aspects including the shortage of the markers used for 
pinpointing cancerous cells and highly resistant nature against radio and 
chemotherapy.  
There are various subtypes of liver cancer encompassing intrahepatic bile duct 
carcinoma, hepatoblastoma, bile duct cystadenocarcinoma, haemangiosarcoma and 
last but with being the most common type of primary liver cancer type by consisting 
around the 85% of all cases, hepatocellular carcinoma(HCC) 
2
. 
HCC, per se enters the list of most common cancer types as seventh, and is the third 
upon evaluation of primary cancer related deaths worldwide (in both sexes) 
3
. 
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Although primary liver cancers including HCC show a differential variability 
worldwide, China makes up for the 55% of all primary liver cancer types due to its 
enormous population and very high age-standardized incidence rates. China is 
followed by the sub-Saharan countries Cameroon and Mozambique 
4
. Mediterranean 
countries including Italy and Greece show intermediate incidence ratios with 20 per 
100.000 people (2%) 
5
. In Turkey, HBV incidence rate is 5-10% and HCV carrier 
rate is 1.5%. HCC incidence rate on the other hand is 1.9% in men, but 1.1% in 
women 
6
. 
1.1.2 Etiologies and Risk Factors of Hepatocellular Carcinoma 
HCC establishment comprises a lengthy, complicated, multi-step condition and 
exposure to numerous factors has a significant contribution in progression of HCC. 
These risk factors include but not limited to viral causes, in case of Hepatitis B or C 
infections (HBV and HCV hereafter), excessive alcohol consumption, frequent 
exposure to toxic substances like Aflatoxin B1 diabetes and chronic liver 
inflammation. The effects of risk factors are expectedly variable, while HBV is the 
leading cause of HCC in Africa, both HBV and HCV accounts for the prime risk 
factors in Asia, although HCV is the most risky factor in the US 
7
. Through 
triggering a set of mechanisms generally starting with inflammation due to damage 
to resident hepatocytes, combined effects of these risk factors finally result in chronic 
liver disease and fibrosis
8
. Additional factors including alcohol consumption, 
diabetes, exposure to toxic compounds such as aflatoxins or pesticides, reactive 
oxygen species (ROS) production, all has contribution in the progression of HCC and 
counted as significant risk factors 
9,10
. 
1.1.2.1 Virus Induced Hepatocellular Carcinoma 
Viral hepato-carcinogenesis is mostly attributable to two distinct viral infections, one 
of which is HBV infection and the second one is HCV infection. Each year around 
320.000 people die because of HBV related diseases, and HCC constitutes the 40-
50% of HBV related deaths 
8
. Some of these infections might be acquired from child-
birth but among the ones that get the disease during adulthood, 30% develops 
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chronic liver disease, which is followed by fibrosis, cirrhosis leading to 
hepatocellular carcinoma at a later stage 
7
. More than 60% of HCC cases are caused 
by HCV and around 20% by HBV in the US, Egypt and Europe. In Asia and Africa, 
the reciprocal scenario applies, however, 60% of all HCC cases is related to HBV 
and 20% is related with HCV infections. There are multiple factors, though, 
determining the rate for fibrotic progression, and there seems to be a variability 
among patients to enter fibrosis, yet the mean progression time is within one or two 
decades 
11
.  
HCV is a positive-sense single stranded RNA virus, the virus genome itself possess 
an open reading frame that encodes a polyprotein. The genes that form the structural 
parts are encoded from the regions close by to 5’, the rest of the genes are encoded 
nearby 3’ region 12. HBV, on the contrary, possess a partially double stranded and 
circular DNA genome, which will eventually give rise to 4 totally different proteins 
that are Surface, Precore, X protein and DNA polymerase 
13
. 
With the further contribution of excessive alcohol consumption, or additional 
infections such as HIV, the disease progression in HCV and HBV related cases 
becomes prevalent to acceleration.  
1.1.2.3 Alcohol and Hepatocellular Carcinoma 
Alcohol abuse is pointed as being one of the primary or else cofactor causing HCC. 
This variability is dependent on the circumstances that a patient bears with, in the 
first case scenario intensive consumption of alcohol may directly trigger HCC or 
through alcohol-induced cirrhosis. In the latter case, this being the cofactor, alcohol 
may act this time as an interplay for a patient, who was diagnosed with HBV or HCV 
14
 . The significant matter at this stage is to determine the amount of alcohol that falls 
between the danger limit and this range is 60-80g of alcohol on a daily basis 
15
. With 
this definition, statistical data verified that around 7% of the people in US are within 
the alcohol abuse limits 
16
. In a study with 464 Italian patients, it was shown that 
people consuming 40-80g of alcohol on a daily basis had a possibility of progressing 
into HCC with an odds ratio of 1.5 compared to the ones, whose alcohol intake is 0-
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40g. More catastrophically, this ratio climbs up to 7.3 fold when the alcohol intake 
passes over 80g per day 
17
. There are various mechanisms relating alcohol to HCC, 
some of which can be listed as the genototoxic effects 
18
, non-genototoxic effects, 
such as the activity of  metabolized intermediate forms of alcohol on liver 
19
, alcohol 
leading to methylation abnormalities 
20
, and finally immune surveillance prevention 
effect of alcohol in tumors 
21
. Some of the mechanisms will be covered in the 
following sections.  
1.1.2.4 Aflotoxin Exposure Induced Hepatocarcinogenesis 
Aflatoxins (Aspergillus flavus toxins) are in essence the metabolites of Aspergillus 
parasiticus and A. flavus. Upon infection of plants, which could be crops, these 
mycotoxins are also produced within the crops upon preservation in moisture areas 
22
. Since coming with an edible food, these toxins potentially exert cumulative 
effects on people, who are frequently consuming them, these effects include 
hepatotoxicity and immunotoxicity. Aflatoxin B1 is the most abundant and extremely 
toxic type of aflatoxins 
23
. Aflatoxin B1-rich areas in Africa seem to be the ones with 
high rates of HCC. Moreover, research suggests that with an additional HBV 
infection Aflatoxin exposure increases the possibility of progression into HCC 
24–26
. 
Therefore the research has suggested that, in majority of the regions that has a 
mutation in p53 gene coincides with the region that possess the highest Aflatoxin B1 
exposure and further data shows Aflatoxin B1 is the responsible factor 
27,28
.  
1.1.2.5 Additional Factors Inducing Hepatocarcinogenesis 
Along with all the risk factors listed and discussed in previous sections, there are 
additional factors with a lower frequency triggering a step forward hepatocellular 
carcinoma. 
To begin with a high-incidence factor, diabetes is an important factor for HCC 
development, it may work as an independent factor, and data suggest that HCC 
development was seen in HCC patients with no other liver disease related factors 
16
. 
Such a tendency may stem from the accumulation of free-fatty acids in the liver 
following insulin resistance in diabetic patients. Build-up of tremendous amount of 
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lipid in the liver starts up a cascade of events leading to hepatocellular injury, 
oxidative stress through radical production by excess lipid metabolism, all of which 
may eventually end up with fibrosis 
2,29
.   
Non-alcoholic liver disorders such as Non-alcoholic fatty liver disorder (NAFLD) or 
non-alcoholic steatohepatitis are also risk factors that by inducing liver damage they 
lead to fibrosis and cirrhosis, which will progressively fire HCC. 
30
.  
HCC can be connected with metabolic disorders, as well, and one of these disorders 
is hereditary haemochromatosis. This disorder is originated from excess iron 
absorption of liver cells that will cause hepatocellular damage in return 
31
. Moreover, 
porphyria  cutanea tarda, which is again associated with extreme iron absorption 
leads to fibrosis and cirrhosis 
32
.  
1.1.3 Molecular Pathogenesis of Hepatocellular carcinoma 
Hepatocellular carcinogenesis can be triggered through different risk factors as 
mentioned in previous sections, and these primary factors are known to be HCV and 
HBV infections, alcohol abuse, exposure to toxic factors like Aflatoxin B1 and 
metabolic abnormalities such as diabetes. 
Either cumulative or individual effects of these risk factors on liver cause damage to 
hepatocytes which will induce necrosis, following excessive cell death, an increase in 
proliferation of hepatocytes is observed. 
This cycle of necrosis-proliferation is known to be progressing in to Chronic liver 
disease 
2
. Continuum of such intensive scarring foster a cirrhosis condition which is 
characterized by nodule formation covered by collagen fibers, during that process 
hepatocytes go under proliferative arrest due to telomere shortening 
33
 (Figure 1.1) 
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Figure 1.1: Multistep pathogenesis of hepatocellular carcinoma (adapted from 
Farazi & DePinho, 2006 
2
). 
With the presence of HBV or HCV, liver enters into a state of inflammation, 
although HCV is cytopathic to the hepatocytes, HBV seems to be non-cytopathic to 
the cells in cell culture 
34,35
. This viral-persistency creates an inflammatory 
environment that renders chronic liver disease continuous with no viral clearance, 
and even presence of virus-specific lymphocytes and natural-killer cells (NK cells) 
are detected at the inflammation sites, activity of those still is not effective enough to 
clear the virus 
36
. HBV and HCV coded proteins affect and change the host gene 
expression, even HBV genome integrates itself into the host genome through which 
it can cause the activation of oncogenes or telomerase activation 
37
. Moreover, the 
oxidative stress and environment created by immune activity is made use of by these 
viruses to activate different signaling pathway to escape apoptosis, cellular 
senescence, and sustain viral-persistence 
38
.  
Following cirrhosis, continuously regenerating hepatocytes turn into hyperplastic 
nodules. The nodules are formed by rather normal cells, yet piled-up genetic 
mutations further develops these hyperplastic nodules into pre-malignant dysplactic 
nodules. With the increased mutations in TP53, MET or E-cadherin genes, these 
dysplatic nodules may progress into hepatocellular carcinoma 
2
. 
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1.1.4 Genetics of Hepatocellular Carcinoma 
Genetic aberrations, although not being completely universal, are very critical 
components that regulate the progression into HCC. Having been discussed, the 
blueprint of HCC formation with rounds of necrosis, inflammation and regeneration 
render the cells to make mistakes during cell division and cell metabolism, as results 
of these defects, tumor suppressor genes may become inactivated and oncogenes 
may get activated 
39
.  
With developing sequencing techniques like exome-sequencing, next-generation 
sequencing and parallel sequencing, previously unknown genetic mutations, gene 
fusions or intra-chromosomal rearrangements are much easier to follow up with. 
Since HCC tumors show a heterogeneity in their genomic sequences, a rather 
targeted therapy should be a possible way to interfere with this mechanism 
40
.  
Accumulating data collected from genomics and transcriptomics studies present 
intermingled subgroups of HCC in terms of genetic mutation tendency. One of the 
highly-mutated pathway seems to be Wnt-signaling pathway elements including 
CTNN1, AXIN1 and AXIN2 with around 50% mutation rate in collected samples, 
whereas TP53 turns out to be a frequently mutating tumor suppressor gene with 
mutations in 20% of tumors 
41
. Just as loss of functions mutations, there are also 
gain-of-function mutations, two of which take place at Chromosome 1p and 8q, 
which leads to the activation of oncogenic genes MYC, SHC1 and MLC1, 
respectively.  
A different study suggests the alteration of genes involved in SWI/SNF complex and 
the genes that are members of interferon and oxidative stress pathways 
42
. 
Furthermore, integrated expression profiling analyses revealed the effects of HBV 
integration into the genome in HCC. First of these is that HBV integrates itself in the 
promoter region of TERT gene, FAR2, IRAK2, MAPK1, MLL2 and MLL4 
43
 . 
Moreover, HBV integration breakpoints are found to be showing a tendency towards 
copy-number-variations, which implies a role for HBV integration in genomic 
instability of HCC 
44
. 
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1.2 Cancer stem cells (CSCs) 
Tumors are embodied from elaborately combined but differentially functioning 
subpopulations of cells. Some of the members of the subpopulations are rapidly 
dividing cells, differentiated cells or the ones that are post-mitotic. Within such 
diversity, a group of cells has been drawing the utmost attention, these are known as 
cancer stem cells (CSCs hereafter). According to the concept of cancer stem cells, 
these cells shelter some of the characteristics of tissue resident stem cells, which 
possess the self-renewal ability and potential to differentiate into more determined 
cell types, which will be investigated in detail in the following sections 
45
.  
1.2.1 Biology of Cancer Stem Cells 
Presence of heterogeneity in tumors was long known, yet with the revisiting of this 
heterogeneity in leukemia fired back the attention on these cells. Engraftment studies 
on acute myeloid leukemia (AML) have shown that grafts could be established only 
in the presence of CD34
+
CD38
- 
cells, even more fascinating result was the 
determination of the responsible fraction which was calculated to be one in a million 
of tumor cells 
46
. Application and translation into the solid tumor has come a bit later 
with the study in solid breast cancer tumors. This work has enlightened the case for 
bulk tumors, and a few CD44+CD24-/low  cells were sufficient to form tumors in 
transplanted xenografts, although thousands of other types were not able to drive the 
same effect 
47
. There are two commonly proposed theories on CSCs, one is 
`stochastic model` and the other one is `hierarchy model`. In stochastic model, all the 
cells in a tumors are assumed to be "biologically equivalent", meaning they all hold 
the same potential to form a tumor and only differentiate in the on-time 
transcriptional factor levels, epigenetic regulations active within the present time and 
this state is not temporary, giving rise to an unpredictable state of cells in a tumor. 
Whereas the hierarchy model suggest that a tumor mass has certain stem cells of its 
own which will both give rise to its own clones, along with it a fraction will 
differentiate into less-potent cell types 
48
.  
The most prominent and suggested aspect of CSCs is their resistance against multiple 
therapeutic approaches, including radiotherapy and chemotherapy and studies show 
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their resistance is owed to having ABC drug pump expression, anti-apoptotic protein 
expression and resistance to DNA damage 
49
. As expected it should be noted that this 
state of resistance to chemo and/or radiotherapy is not universal for all cancer types 
50
.  
Another suspect against CSCs is on their responsibility for tumor relapse upon 
surgical removal, or assumed clearance after chemo-or-radiotherapy. Even 
recurrences at different locations were detected, which opens the next characteristic; 
their role in metastasis. In pancreatic tumors, a subpopulation of CSCs, which were 
identified by the markers CD133
+
CXCR4
+ 
, were shown to be responsible for the 
type of tumors, it was the same study, which offered that upon ablation of 
CD133
+
CXCR4
+ 
subpopulation metastasis ability in the cell lines were halted, 
although tumorigenesis was maintained 
51
.  
1.2.2 Selected Markers of Cancer Stem Cells 
Marker selection in determination of CSCs is one of the essential steps in pursuit of 
their presence and metabolism. Along with having various markers, marker 
definition is still a controversy between scientific communities. The markers for 
CSCs, in its essence, are also the markers used in the detection of tissue resident 
adult stem cells. CD34 and CD38, as examples, are very well-established 
hematopoietic stem cell markers, and are the most trusted markers of leukemia 
46
. 
CD133 (Prominin-1) is a widely accepted CSC marker found in the stem cells of 
different tissues and organs, such as colon and brain 
52
. Figure 1.3. summarizes the 
percentage of potential CSCs and Table 1.1 describe function and phenotypes of 
commonly used cancer stem cell markers for hepatocellular carcinoma. 
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Figure 1.2: CSC marker preference percentage by the scientific communities (adapted 
from Razvi, 2014 
53
). 
Among these markers, CD133 and EpCAM are the most frequently preferred and the 
most trusted markers for HCC 
54–58
. CD133, within its origin, is a pentaspan 
membrane protein  and is the first member to be identified in the prominin family of 
proteins, which specifically gives the name for it, Prominin-1 
59
. Although its exact 
association with a certain pathway is not established yet, expression in specific type 
of cells was observed, as an instance, CD133 expression was considered to be the co-
expressed marker for CD34+ hematopoietic stem cells 
60
.  
Table 1.1: Commonly used cancer stem cell markers for hepatocellular carcinoma
54
. 
Cell Surface Marker Suggested Function in CSCs Phenotypes of CSCs 
CD13 ROS-induced DNA damage 
reduction 
Tumorigenic, cell cycle arrest, 
chemoresistant 
CD24 STAT3-mediated Nanog 
regulation 
Tumorigenic, chemoresistant 
CD44 Regulation of redox status Tumorigenic, invasive 
CD90 Unknown Tumorigenic, metastatic 
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CD133 Neurotensin/IL-8/CXCL1 
signaling 
Tumorigenic, chemoresistant 
DLK1 Unknown  Tumorigenic, chemoresistant 
EpCAM Activation of Wnt signaling Tumorigenic, invasive, 
chemoresistant 
OV6 Unknown Tumorigenic, invasive, 
chemoresistant,  
There has been several studies indicating involvement of CD133 expression in CSCs, 
in one of which CD133+/CD34+ cells has shown to be responsible for a rather 
improved clonogenic capacity when engrafted 
61
 . 
An alternative study suggested that CD133+/CD44+ double positive cells were more 
resistant to chemotherapy due to increased ABC super family transporters in HCC 
55
. 
EpCAM (CD326), an epithelial  cell adhesion molecule, is initially identified as a 
liver stem/progenitor cell marker, found in oval cells 
62
.  EpCAM association with 
CSCs is described with numerous studies, one of which states the concentrated 
presence of EpCAM+/AFP+ cell population at the tumor  invasion border in HCC, 
and HCCs with such phenotype exhibit poorer survival. Moreover, EpCAM is shown 
to be a target for Wnt signaling pathway, and the study has shown that activation of 
beta-catenin has increased the spheroids formed in soft agar in HCC cell lines 
63
.  
1.2.3 Cancer Stem Cells and Hepatocellular Carcinoma 
As seen in other cancer types, CSC markers were also detected in HCC samples and 
cell lines (Table 1.1). Cancer-stem-cells of the liver and/or HCC may expresses 
markers in different combinations depending of the cell lines or the sample. Yet, the 
most common feature of this population is to have the ability to form engrafted 
tumors upon injection in mice 
64
. One of the clearest ways to point out the existence 
of CSC in HCC is through markers  
Normally, hepatoblasts, the progenitor cells of hepatocytes and cholangiocytes,  
express cytokeratin-19 (CK19), EpCAM and AFP 
65
. CSCs and liver stem cells also 
share a set of markers, for instance although EpCAM and CD133 are normal liver 
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stem cell markers, their double positivity in HCC correlates with the differentiation 
ability of the cells, colony formation ability and resistance to chemo-therapy 
56
. 
Another study has shown the increase in tumorigenicity in vivo upon transplantation 
of CD133+/ALDH+ cells compared to their CD133-/ALDH+ or CD133-/ALDH- 
counterparts 
58
. Several models were proposed to describe tumor initiation model for 
HCC. Following scheme encompasses these models (Figure 1.4)  
 
Figure 1.3: CSC based tumor initiation model in HCC (adapted from Ji & Wang 
2013
66
) 
1.2.4 Signaling Pathways in CSCs and HCC 
Multiple efforts were consumed on defining the signaling pathways that 
differentially regulated during CSC reprogramming. The need for plenty of 
additional studies to separate mingled pathways is inevitable, yet existence of a 
complex cross-talk of pathways was observed in the process of CSC formation 
67
. 
Numerous signaling pathways involving i)Wnt, ii)Notch, iii)AKT, iv)transforming 
growth factor beta (TGF-beta) and v)STAT3, were shown to be altered compared to 
their natural states. Such a diverse variety may be linked to the alternative origins of 
CSCs 
66
.  
Wnt/β-catenin pathway has significant roles during development, stem cell 
maintenance and its involvement in CSC metabolism, and currently under the lights 
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of new findings, it is gaining more and more importance. There are studies showing 
the activity of Wnt/β-catenin signaling in hepatic CSCs maintenance 54. What's more, 
is activation of Wnt signaling was detected to be increasing EpCAM+CSC levels in 
HCC 
68,69
.  
Altered TGF-β signaling through activation of IL-6/STAT3 system in hepatic 
progenitor cells lead to misguided differentiation and progress into HCC 
70
. In terms 
of CSC population, TGF-β pathway was indicated to control CD133+ cell population 
in HCC, additionally, chemo-resistant character of EpCAM+ CSCs was affected by 
IL-6/STAT3 activity 
71,72
.  
AKT signaling activation was found to be attributing to the chemo-resistant nature of 
CSCs. Hypoxia-inducible factor1-α (HIF1α) production was observed under hypoxia 
conditions by the activity of Akt signaling, which later forms a positive feedback 
mechanism. Following HIF1α expression, platelet-derived growth factor (PDGF) and 
vascular endothelial growth factor (VEGF) upregulation, both of which are known to 
be effective in chemo-resistance, in addition, Akt signaling trigger a set of 
mechanisms which eventually lead to increased expression of ABCG2 (a drug efflux 
transporter) 
71,73
.   Interaction between AKT, TGFB, IL6/STAT3 and WNT/B-
Catenin axis is summarized in Figure 1.5. Combined intricate actions of these 
pathways leads to i) self-renewal, ii) differentiation, iii) tumorigenicity, iv) chemo-
resistance thereby culminating into increased v) cell survival.  
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Figure 1.4: Signaling pathways involved in hepatic cancer stem cells (adapted from 
Ji & Wang 2013 
66
). 
1.3 Notch signaling pathway 
Knowledge on Notch signaling pathway lay down its roots back in 1900s. Although 
having been worked on almost a century now, there is plenty of questions yet to be 
answered on involvement of Notch signaling in multiple biological events. Notch 
gene was discovered, originally, in fruit fly, Drosophila melanogaster, in a mutated 
form it leads to a nicked wing margin phenotype, and inherited as a sex-linked 
mutation 
74,75
. Notch receptor family involves 4 members (Notch1-4) in 
mammalians, all of which are produced in precursor form and cleaved through furin-
like convertase, also known as, S1 cleavage, to become mature receptor 
76
. Mature 
form of the receptor is a combination of its two subunits, one is facing the 
extracellular domain (ECD), and the other has a trans-membrane, as well as an 
intracellular domain (ICD, later will be referred as Notch ICD (NICD)). ECD 
possess several repetitive regions including epidermal growth factor (EGF) -like 
repeats and LIN2 and Notch repeats (LNRs), enables signaling only in the presence 
of the ligand, NICD has PEST domain and is the activated form 
77
, (Figure 1.6).   
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Figure 1.5: Notch signaling pathway (adapted from Guruharsha et al., 2012 
78
) 
A specific feature of Notch signaling is its activation only in the presence of a 
physical cell-to-cell contact through the ligands of the neighboring cell. These 
ligands are known as DSL (Delta-Serrate-LAG2) proteins and the members of DSL 
family of proteins in mammalian cells are jagged-1(JAG1), jagged-2(JAG2), Delta-
like-1(DLL1), DLL2 and DLL3 
76
. Binding of the receptor to the ligand ends up with 
a conformational twist, which makes the ECD susceptible to metalloproteinase tumor 
necrosis factor alpha converting enzyme (TACE or ADAM17) and results in S2 
cleavage. This cleavage triggers the next cleavage and subsequent release of NICD 
into the cytoplasm. S3 cleavage is mediated by presenilin-γ-secretase complex 
sheltering nicastrin (NCSTN), presenilin 1 and 2 (PSEN1, PSEN2), anterior pharynx 
defective 1 (APH1) and presenilin enhancer 2 (PEN2) 
77,78
.  
Following S3 cleavage NICD translocates to nucleus and form a complex with 
CBF1-Su(H)-LAG1 (CSL) and replaces its repressor activity into a transcriptional 
activator by recruiting Mastermind-like 1 (MAML1). This activation leads to 
sequential events leading to expression of cyclin D1, Notch ligands and receptors and 
many more 
79
. In case of a turnover of the Notch receptor, it is phosphorylated at its 
PEST domain by ubiquitin E3 ligases such as SEL10 (FBXW7) to be directed to 
proteasomal degradation 
80
.   
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Notch signaling has pivotal roles during development, such as; i) cell-fate 
determination, ii) proliferation and iii) apoptosis, studies has shown the context 
dependent nature of Notch signaling 
77
. Along with controlling stem cell 
maintenance, it directs neurogenesis by contact-inhibition, additionally has a crucial 
role during angiogenesis 
81,82
. Involvement of Notch signaling in CSC 
reprogramming and HCC is also an essential part and will be touched upon in the 
following sections. 
1.3.1 Notch signaling in CSCs and HCC 
Integrative role of Notch signaling in the maintenance of the stemness state of the 
stem cells has been known from earlier studies (Figure 1.7).  One of such kind of 
regulation is seen in neural cells, in control of HIF1-alpha Notch acts as a guard for 
the precursor form of the neural stem cells, keeping them at an undifferentiated state, 
in case of Notch loss medullablastoma tendency was observed 
79
. Expectedly, upon 
halting of Notch signaling in these cells, precursor cells were observed to be 
differentiating, supporting the action of Notch in the maintenance of stemness 
80
.   
An alternative study has shown the role for the stem cell programming ability of 
Notch in which activation of Notch signaling by various ligands exerted its effects as 
an increase in  mammary stem cells and a ten-fold boost mammosphere formation 
81
. 
These different illustrations of Notch activity in potential CSC like ability formation 
strengthens the view of involvement of Notch signaling in cancer stem cell 
reprogramming. There are some studies showing the aberration or in some cases 
inhibition of Notch signaling in HCC and other cancer types but not much is still 
known to discover the role of Notch in HCC 
82
. 
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Figure 1.6: Notch signaling crosstalk with other signaling pathways in 
carcinogenesis (adapted from Ranganathan et al., 2011 
83
). 
1.4 Involvement of Toll-like receptors in HCC 
In consideration of humans, there are known ten types of toll-like receptors(TLR), 
which are known to be involved in the identification of pathogen associated 
molecular patterns (PAMPs), and this renders them to possess the name pathogen 
recognition receptors (PRRs) 
84
. TLRs can be simply categorized into two, one is 
formed by the cell-membrane located receptors that recognize modified lipids or 
protein based ligands (TLR1,2,4,5,6,10,11 and 12), and the second type is located at 
the endosomal compartments (TLR3, 7/8 and 9) and recognize mostly foreign 
nucleic acids 
85
. TLRs contain three major domains one is required for ligand binding 
another is for single membrane-passing and the third domain is cytosolic Toll/IL-1R 
(TIR) domain. Signal transfer occurs through two main downstream ways, first is 
called a Myddosome, which involves an adaptor protein dimerization with the 
receptor and is called myeloid differentiation primary response protein 88 (MyD88) 
that activates nuclear factor-kappa B(NF-κB). Another complex is Triffosome that 
involves interferon(IFN)-regulatory factors(IRFs) which bind to TIR domain 
containing adaptor protein inducing IFN-beta (TRIF) 
85
. Each TLR is induced by a 
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different agent, TLR2 heterodimerizes with TLR1 and TLR6 and recognizes triacyl 
or diacyllipoproteins 
86,87
. TLR5 homodimerize upon bacterial flagellin presence 
88
 
and TLR4 is activated by lipopolysaccharide (LPS) 
89
. TLR7 TLR8 and TLR9 are 
located on endosomes, and although TLR7 and TLR8 are activated by single-
stranded RNAs (ssRNAs), TLR9 responds to unmethylated CpG oligonucleotides 
and finally TLR3 respond to double-stranded RNA 
90–93
. Although there are not 
many studies involving TLRs and hepatocellular carcinoma, some studies suggest 
that TLR4 induction, for instance, in HCV bearing mice, upon alcohol exposure led 
to HCC, in which the stemness have found to be increased when CD133 levels were 
investigated 
54
. A very recent study shows the potential involvement of TLR7 and 
TLR9 on their ability of HCC tumor formation in mice 
94
. Yet, the effects of TLRs 
on cancer microenvironment in HCC or tumor therapy is yet to be investigated.  
1.5 Cancer-immunotherapy 
Molecular and individual identity of a tumor is unique, and through making use of 
this concept immuno-therapies are trying to be developed against multiple cancer 
types. These so-called "cancer vaccines" are aimed to direct the fighters of the 
immune system to prevent tumors from expanding and growing. There are several 
advantages of the usage of cancer vaccines, accumulating knowledge on viral based 
vaccines showed the world how immune system works to treat the malignancies 
within itself, and this strategy supplied a blueprint for the immunization  for cancer 
antigens 
95
. There are challenges, of course, within this strategy, antigen promoting 
must be achieved by dendritic cells, immune suppression by the tumor 
microenvironment must be overcome with, and protective T cell responses should be 
activated 
96
 along with NK cell activity in cases missing self is an issue. 
TLR agonist usage in cancer immunotherapy is recently becoming a preferred topic. 
TLR agonists lead to immunostimulatory effects, which could be activation of co-
stimulatory molecules (CD86, CD40 and CD80) that are located on dendritic cells 
(DCs). Moreover, they induce the inflammatory cytokine (TNFα and IL-12) 
secretion and polarize T cells to assume Th1 fate 
97
. By using these 
immunostimulatory effects of vaccines can be developed with the addition of desired 
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cocktails to treat the tumor masses. This technique is called "Combination 
immunotherapy" and it makes use of gathering different agents such a signaling 
pathway inhibitors, immunostimulatory molecules, or cell based therapies together. 
By making use of the immunostimulatory potential of small molecules in 
combination with TLR ligands, a better approach to overcome the 
immunosuppressive environment existing at the tumor niche could be made possible 
98
. 
1.6 Aim of the Study 
Cancer stem cells are shown to be present in solid tumors of various cancer types 
99
. 
Although forming only a small subpopulation in a tumor, cancer stem cells are 
known to be responsible for chemo-and-radio-therapy resistant disposition of cancer, 
along with being in charge of the recurrences upon surgical removal of a tumor mass 
100
.  Existence of CSCs in HCC is also known, which can be explanatory for the 
chemotherapy and radiotherapy resistant nature of HCC tumors 
66
.  
Notch signaling aberrations are detected to be present in HCC. Involvement of Notch 
signaling in stem cell regulation, mostly in favor of the maintenance of stemness 
during embryogenesis and also abnormal deregulation of Notch activity in CSCs of 
several cancer types, directed us to interrogate the activity of Notch signaling in 
HCC cancer stem cells 
78
.  
Importance of TLRs in the therapy of solid tumors are gaining more attention with 
the piled up evidence of recent studies 
97
. Immunostimulatory effects of TLR ligands 
will be analyzed to eradicate large tumor mass. In this study, expression levels of 
TLRs in HCC cell lines were investigated to decide on the potential applicability of 
TLR ligand therapy in vivo by checking the effects of TLR ligands on expression 
levels of TLRs in cell lines.  
Upon completion of this work, existence of the CSCs in certain HCC cell lines and 
the role of Notch signaling on cancer stem cell population will be characterized in 
order to propose a solution to treat HCC. The ultimate goal in this study was to 
establish a cancer immunotherapy method, depending on the in vitro data acquired 
from  Notch experiments on cancer stem cells and the data showing the possible 
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candidate TLRs to be upregulated in cell lines upon stimulation, to achieve tumor 
shrinkage or even eradication.   
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Chapter 2 
2. Materials and Methods 
2.1. Materials  
2.1.1. General Laboratory Reagents  
The reagents highly used in the experiments including Ethanol, Bradford reagent and 
methanol, haematoxylin were analytical grade and were purchased from Merck 
(Darmstadt, Germany) or Sigma-Aldrich (St. Louis, MO, USA). ECL Prime western 
blotting detection kit and Hybond nitrocellulose western blot membranes were 
purchased from Amersham Pharmacia Biotech Company. DMSO and Ponceau S 
were bought from Applied Biochemia (Darmstadt, Germany). Fixative Medium A 
was purchased from Invitrogen (GAS003, Carlsbad, CA, USA).  
2.1.2. Tissue Culture Reagents and Materials 
 Media used in cell culture including Dulbecco’s modified Eagle’s medium (DMEM) 
and Roswell Park Memorial Institute (RPMI) 1640 medium and OptiMEM were 
purchased from GIBCO (Invitrogen, Carlsbad, CA, USA). Supplemental reagents 
such as Penicillin/streptomycin antibiotics, L-glutamine, Non essential amino acids 
(NEAA), fetal calf serum (FCS) and Trypsin-EDTA were also purchased from 
GIBCO. All of the plastic materials used in cell culture like flasks, Petri dishes, 
multi-well-plates, cryotubes were purchased from Corning Life Sciences Inc. (USA). 
All sterile serological pipettes were purchased from Costar Corporation (Cambridge, 
UK).   
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2.1.3. Polymerase Chain Reaction (PCR)  
OneTaqMM Quick-Load 2XMM w/Std buffer was used as a ready-to-load master 
mix. 
2.1.4. Primers 
Primers used throughout this study were designed by using Primer Designer 3.0 
Program (http://frodo.wi.mit.edu/primer3/input.htm). All the primer pairs were 
blasted against the human genome (http://www.ncbi.nlm.nih.gov/BLAST/) 
Table 2.1.: Primers pairs involved in this study are enlisted as depicted below. 
Gene 
name 
Forward Primer Reverse Primer 
hTLR1 5’-CATAACTCTGCTGATCGTCACC-3’ 5’-TGCTAGGAATGGAGTACTGCG-3’ 
hTLR2 5’-GATGACTCTACCAGATGCCTCC-3’ 5’-CAGAAGAATGAGAATGGCAGC-3’ 
hTLR3 5’-CTCAGAAGATTACCAGCCGC-3’ 5’-TTCTAGTTGTGGAAGCCAAGC-3’ 
hTLR4 5’-TTACCTGTGTGACTCTCCATCC-3’ 5’-CAGAAGAATGAGAATGGCAGC-3’ 
hTLR5 5’-CCTTGACTATTGACAAGGAGGC-3’ 5’-TTGTAGGCAAGGTTCAGAACC-3’ 
hTLR6 5’-TCTCATGACGAAGGATATGCC-3’ 5’-CGATCAGCAGAGTTATGTTGC-3’ 
hTLR7 5’ACGAACACCACGAACCTCAC-3’ 5’-GGCACATGCTGAAGAGAGTTAC-3’ 
hTLR8 5’-TGGCTTGAATATCACAGACGG-3’ 5’-ACCAGGCAGCATTAATCTTCC-3’ 
hTLR9 5’-CAACAACCTCACTGTGGTGC-3’ 5’-GAGTGAGCGGAAGAAGATGC-3’ 
hTLR10 5’-GAACTGATGACCACCTGCTCC-3’ 5’-GAAGTCTTGATTCCATCACGC-3’ 
hGAPDH 5’-ACCACCATGGAGAAGGCTGG-3’ 5’-CTCAGTGTAGCCCAGGATGC-3’ 
  
40 
 
2.1.5. Agarose Gel Electrophoresis 
Horizontal gel electrophoresis apparatus was Thermo EC Midicell Primo EC330.  
The power supply and eletrophoresis gel system were EC250-90, they were both 
from Thermo Scientific (MA, USA). Alternative power supplies used in experiments 
were Power-PAC300 and Power-PAC200, both from Bio-Rad Laboratories (CA, 
USA).  
2.1.6. Spectrophotometry 
Protein concentration measurements of Bradford assay were done by using Beckman 
Du640 spectrophotometer from Beckman Instruments Inc. (CA, USA). 
2.1.7. Determination of Gene Expression 
2.1.7.1. Total RNA Isolation  
Phenol-Chloroform extraction method was followed for RNA isolation from 
cultured-cells.  
2.1.7.2. First Strand cDNA Synthesis 
ProtoScript M-MuLV First Strand cDNA synthesis kit from New England Bioloabs, 
Inc. (MA, USA) was used for the first strand cDNA synthesis. 
2.1.8. Antibodies 
Antibodies, both primary and secondary, were purchased from a variety of 
incorporations. Information denoting the catalog number, working conditions, and 
company name were listed in Table 3.  
Table 2.2: Listed version of the antibodies used in this study 
Antibody Name Company and 
catalog number 
Western Blot 
Dilution 
Immunostaining 
Working Dilution 
Calnexin Sigma-Aldrich, C4731 1:5000  
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α-tubulin Calbiochem, CP06 1:5000  
Anti-mouse-HRP Sigma-Aldrich, A0168 1:5000  
Anti-goat-HRP Abcam, Ab6741 1:5000  
Anti-rabbit-HRP Sigma-Aldrich,6154 1:5000  
β - Actin Sigma, A5441 1:10000  
Anti-mouse/rabbit 
Alexa Fluor 488 
Invitrogen, A11034  1:750 (IF) 
Anti-mouse/rabbit 
Alexa Fluor 586 
Invitrogen, A11034  1:750 (IF) 
Sox9 Millipore, AB5535 1:1000 1:1500 (IF) 
HNF4α Santa Cruz 
Biotechnologies, sc6556 
1:300 1:150 (IF) 
CD133 (pure) Miltenyi, 130-090-422  1:100 (IF/IP) 
CD133-APC Miltenyi, 130-090-826  1:30 (Flow 
Cytometry) 
EpCAM-FITC Miltenyi, 130-080-301  1:30 (Flow 
Cytometry) 
Annexin V - FITC BD Pharmingen, 556419  1:20 (Flow 
Cytometry) 
Propidium Iodide 
Solution 
BioLegend, 421301  1:10 (Flow 
Cytometry) 
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2.1.9 Immunoperoxidase Assay Reagents 
DAKO Envision + system was purchased from DAKO (Glostrup, Denmark). 
2.1.10 TLR Ligands 
TLR ligands used in this study were supplied from several companies. 
Lipopolysaccharide (LPS) (isolated from E.coli; Sigma, USA), peptidoglycan (PGN) 
(isolated from B.subtilis; Fluka, Switzerland), pI:C (Amersham, UK), R848 
(Invivogen, USA), LTA (Invivogen, USA), Resiquimod (Invivogen), K23 (Alpha 
DNA, Canada), Flagellin (Sigma, USA). 
Sequence for K23 is as follows: 
K23 (12mer) : 5’-TCGAGCGTTCTC-3’, phosphoryl(thio) manufactured.  
2.2. Solutions and Media  
2.2.1. General solutions 
50X Tris-Acetate-EDTA Buffer  242 g Trisma base, plus 100 mL of 0.5 M 
EDTA (pH: 8.0), plus 28.55 mL of Glacial 
Acetic Acid were combined and overall 
completed to 1L with ddH2O. Working 
dilution: 1X 
10X Tris buffered saline (TBS) 12.9g Trisma base and 87.76g NaCl 
combined in 1 L ddH2O.  
pH adjustment : 8.0.  
Working dilution: 1X. 
 12.1 g of Trisma was dissolved in 100mL of 
ddH2O.  
pH adjustment : 6.8 
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1,5M Tris HCl 18.1 g Trisma base was dissolved in 100 mL 
of ddH2O.  
pH adjustment: 8.8. 
10X Phosphate Buffered Saline 
(PBS) 
80g NaCl, 14.4g Na2HPO4, 2g KCl, 2.4g 
KH2PO4 were combined in 1 liter of ddH2O. 
Working dilution: 1X. 
2.2.2. Tissue culture solutions 
DMEM/RPMI media  In order to prepare complete medium 1% 
Non-essential amino acids (NEAA), 1% 
Penicillin/Streptomycin, 10% Fetal Calf 
Serum (FCS) all added to supplied 
commercial medium. Keep at 4°C. 
10X Phosphate buffered saline (PBS) 80g NaCL, 14.4g Na2HPO4, 2.4g KH2PO4, 
2g KCl were all dissolved in 1 L ddH2O.  
Working dilution: 1X. 
Storage Temperature: 4°C. 
2.2.3. Immunofluorescence Staining Solutions 
4% Paraformaldehyde 4g paraformaldehyde was dissolved in 
100mL ddH2O, solution heated at 130°C for 
1 hour. Let cool down before use. 
4% Formaldehyde 100mL of 40% Formaldehyde was 
dissolved in 1L ddH2O. 
Blocking solution 0.2% PBS Tween-20 with 10% FCS 
Washing buffer 0.2% Tween-20 dissolved in 1XPBS. 
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DAPI (4’,6-diamidino-2-
phenylindole) Stain  
Prepared as 1μg/ml solution in ddH2O. 
2.2.4. Immunoperoxidase Staining Solutions 
Fixation solution 1:1 ratio solution of Acetone: Methanol, 
mixed and stored at -20°C 
Blocking solution 10%FCS and 0.3% TritonX-100 solution 
prepared in 1XPBS. 
Washing solution 0.3% TritonX-100 dissolved in 1XPBS 
3% H2O2 solution Prepared as 6mL 30% H2O2 added to 20mL 
methanol and 34mL ddH2O solution. 
DAB reagent Chromogen and substrate were mixed as 
described in DAKO Envision + Dual Link 
System-HRP kit. 
2.2.5. Sodium Deodecyl Sulphate (SDS)-Polyacrylamide Gel Electrophoresis 
(PAGE) and Immunoblotting Solutions  
10X Tris buffered saline (TBS) 12.9g Trisma base + 87.76g NaCl in 1L of 
ddH2O. 
pH adjustment: 8.0  
Working dilution:  1X. 
10X SDS Running buffer  144g Glycine + 30g Trisma base and 50mL of 
10% SDS were mixed in 1L ddH2O. 
 Working dilution: 1X. 
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10X Transfer buffer 72g Glycine + 58g Trisma base + 2mL of 10% 
SDS dissolved in 1L ddH2O. 
Working dilution is 1X, and this solution includes 
10-20% Methanol (depending on the experiment 
setup).  
TBS-Tween 20 0.2% Tween 20 dissolved in 1X TBS. 
Ponceau S  0.1% (w/v) Ponceau S and 5% (v/v) acetic acid 
prepared in ddH2O. 
Blocking solution 0.2% TBS-Tween 20 was prepared. Non-fat dry 
milk or bovine serum albumin (BSA) was added 
to the solution to get 5% (w/v) final ratio. (Usage 
of dry milk or bovine serum is determined 
according to the antibodies.) 
2.2.6. Preparation of DAPT and rhJagged-1 
DAPT was purchased from Sigma-Aldrich Chemie GmbH (MO, USA). 
Recombinant human Jagged-1 Fc Chimera was purchased from R&D Systems (MN, 
USA) Recombinant human Jagged-1 was reconstituted at 200μg/mL in sterile PBS as 
described in manufacturer’s protocol. Working concentration for rhJagged-1 was 
50ng/ml. DAPT was reconstituted at 18mg/mL in sterile DMSO. Working 
concentration was 50uM. 
2.3. Methods 
2.3.1 Tissue Culture Methods 
2.3.1.1 Cell Lines and Growth Conditions of Cells 
Various hepatocellular carcinoma cell lines were studied throughout this work. Some 
of these cell lines including FLC4, FOCUS, Hep3B, Hep40, HepG2, Huh7, 
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PLC/PRF/5, Mahlavu, and SK-HEP-1 were cultured in DMEM. Rest of the cell lines 
SNU182, SNU387, SNU398, SNU423, SNU449, and SNU475 were kept in RPMI 
medium. Supplemental media including 10% fetal calf serum, 1XNEAA, 2mM L-
Glutamine and 100 units of Penicillin/Streptomycin were added to DMEM and 
RPMI to acquire their complete forms. Cultured cells were incubated at 37°C with 
5% CO2 maintenance. Before usage, all media were pre-heated to warm up until 
37°C. 
2.3.1.2    Passaging Cells 
Adherent HCC cell lines were passaged before reaching complete confluency. 
Following the transfer of plates from incubator to hood, the old media was aspirated 
and washed once with sterile 1XPBS. Having been washed with PBS, and the 
consequent aspiration of PBS, Trypsin-EDTA was dropped equally over the cells to 
make them detach from the surface. With the addition of Trypsin-EDTA plates were 
put back into the incubator, which was set for 37°C with 5% CO2 maintenance. Upon 
detachment of the cells from the bottom of the plates, fresh sterile media was added 
onto the cells to halt the action of trypsin (meanwhile, it is important to keep cells in 
Trypsin as short as possible to prevent any damaging to cell surface). With pipetting, 
cells were distributed as single cells and divided into different dilutions according to 
the experimental requirements. 
2.3.1.3    Thawing and Cryopreservation of Cells 
Thawing of cells required important amount of caution, upon removal of cells from 
liquid nitrogen, cells were placed on ice to prevent their contact from warm air. 
Cryotubes were immediately put in water bath, which was pre-heated to 37°C. After 
the ice in the vials melted, cells were transferred into a 15mL falcon tube having 
5mL of the preferred media. By pipetting the cells were carefully gotten rid of 
DMSO, which is toxic to cells. Then, the falcon was centrifuged at 1600rpm for 4 
minutes. After centrifuge supernatant was aspirated and the pellet was re-suspended 
with fresh complete media, and put in petri dish.  The dish was then placed into the 
incubator, which was set for 37°C with 5% CO2 maintenance. 
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Cells reaching around 60-80% confluency were counted as “freezable”. For this 
process, old media was aspirated and washed once with 1XPBS. Upon aspiration of 
PBS, Trypsin-EDTA solution was dropped over cells, and plates were incubated at 
37°C for 5 min. After collecting trypsinized cells in a falcon, cells were centrifuged 
at 1500 rpm for 4 mins and the supernatant was aspirated. In the meantime, a 
“freezing media” containing 70% of the preferred medium, 20% FCS and 10% 
DMSO was prepared. This media was placed on the cells and following re-
suspension cells were transferred into a cryovial labeled beforehand. The cryovial 
was placed in -20°C for 45-60 min. The vials were then transferred to -80°C fridges. 
Within 7-10 days cells were placed into liquid nitrogen in order to store them for 
longer periods of time. 
2.3.1.4    Treatment of Cells 
Treatment of the cells has taken place in differential conditions from serum free 
media to complete media. For the marker assays, either 24 or 72 hours after cell 
seeding the complete media was removed, washed once with 1XPBS and replaced 
with media containing 0.001% FCS with 1mM Na2SeO3. For Jagged-1 and DAPT 
treatments, after preparing the components in desired concentrations, cells were 
treated after 24 or 72 hours following cell seeding, with their controls such as PBS or 
DMSO. In case of TLR ligands experiments, cells were seeded, waited overnight and 
treated with different TLR ligands, 4 hours following treatments, cells were 
trypsinized and prepared for RNA isolation.  
2.3.2 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analyze the products of PCR analysis. For 
this process, Agarose was weighed to be 1.5% (w/v) and dissolved in 1X TAE buffer 
by melting in microwave. Having gone through the melting step, EtBr (10µg/mL) 
was mixed with the agarose gel, and poured into the tray; appropriate comb was 
chosen and placed to the tray, as well. The gel was left for cooling under fume hood 
until it solidifies. Following solidification, the comb was removed and the tray is 
placed in the gel tank previously filled with fresh 1X TAE.  Since the PCR products 
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were already ready-to-load products, samples were loaded into the gel in desired 
order. A DNA ladder was used as a marker to understand the band pattern. Following 
loading the tank lid was closed and run with 100V until the desired band separation 
was achieved. With the end of running, the gel was taken under visualization device, 
which uses Chemi-Capt software for image acquisition (Vilber Lourmat, Paris, 
France).   
2.3.3 Total RNA Extraction from Cultured Cells 
Before isolation cells were scraped and pipetted with cold media, and then cells were 
transferred into a 15mL falcon tube. The tube was centrifuged at 2500rpm for 5 min. 
at 4°C. The supernatant was aspirated and 1mL Trizol was added on top of the pellet. 
Up-down the cells thoroughly, at this stage cells coulc be stored at -80°C for 1 week , 
if desired. Upon the addition of Trizol cells were mixed and transferred to a 1.5 mL 
eppendorf tube, 200μL of chloroform was added to the mixture. Shaken vigorously 
for 15sec, and left at room temperature for 3min.Next phase-separation step takes 
place, for this tubes were centrifuged at 13200rpm for 17min. at 4°C. Next was an 
important step, only the top phase was taken without disturbance to any other layers, 
which would result in DNA, and cellular content contaminations. The top-phase was 
transferred into a new eppendorf and 500μL isopropanol was added and mixed 
gently, left to sit at RT for 10min. Then, the tubes were centrifuged at 14000rpm for 
10 min at 4°C. Following centrifugation, isopropanol was removed and 1mL 75% 
EtOH was added to the tube, vortex shortly, until the white flake moved from its 
place. The tube was centrifuged at 8000rpm for 8min. at 4°C. Next, 75% EtOH was 
removed and 99.8% 1mL EtOH was added to the tube and vortexed shortly and put 
in centrifuge at 8000rpm for 8 min. at 4°C. Having gotten rid of the EtOH pellet was 
put in a container and placed under fume hood to remove remaining EtOH. After 10-
15min. the pellet was dissolved in 20-30μL of Nuclease-free ddH2O. RNA samples 
were checked under Nanodrop 2000 for their purity and contamination scores and 
transferred to -80°C for storage.  
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2.3.4 First Strand cDNA Synthesis 
For cDNA synthesis, ProtoScript M-MuLV First Strand cDNA synthesis kit from 
New England BioLabs, Inc. (MA, USA), was used by following manufacturer’s 
protocol. For this procedure, 1µg of total RNA was mixed with 2µL of Oligo 
d(T)23VN primer and the total volume was completed to 8 µL  by Nuclease-free 
H2O. Tubes were spun down for 3-5 sec. and put in the machine for pre-denaturation 
program which was set to 70°C for 5 min. After program ending, a mixture of 10µL 
M-MuLV Reaction Mix and 2µL M-MuLV Enzyme Mix were added onto the tubes, 
spun down for 3-5sec and put in the machine with cDNA program, which was set as 
42°C for 60min., 80°C for 5min., and 4°C for 10min. which made a cycle 35 times. 
After synthesis cDNAs were stored at -20°C for short-term store. 
2.3.5    PCR 
For PCR OneTaq
MM 
Quick-Load 2XMM w/Std Buffer from New England BioLabs, 
Inc. (MA, USA) was used. The protocol for PCR sample preparation is shown in 
Table 2.3. 
Table 2.3: Reagents used in PCR preparation. 
Reagent Volume 
2xDyNAyzme II Master Mix (F-508) 12,5 µL 
Nuclease-free H2O 9.5 µL 
10pmol Forward Primer 1 µL 
10pmol Reverse Primer 1 µL 
cDNA 1 µL 
Total Volume 25 µL 
Human TLR primer Running conditions are: 
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94°C for 10 sec. 
62.5°C for 20 sec.         35 cycles    
72°C for 60 sec.  
After PCR samples were loaded into agarose gels as desired. 
2.3.6 Total Protein Extraction from Cultured Cells 
Cultured cells were trypsinized, and centrifuged at 1600rpm for 4 min. Following 
centrifuge the pellet was dissolved in 1X PBS and tubes were placed on ice. RIPA 
buffer (150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS (sodium dodecyl sulphate), 50 mM Tris, pH was adjusted to 8.0. Buffer should 
be prepared freshly and just before use, 1X Protease inhibitor (PI) cocktail must be 
added to the buffer) was added on top of the cells in a volume of 2:1 (RIPA: pellet 
volume) and the tubes were vortexed. Cells were left in ice for 30 min to be lysed 
and tubes were vortexed ever 5 min. When lysis was over samples were sonicated for 
10 sec. at 4°C and transferred into 1.5mL eppendorf tubes and centrifuged at 
13000rpm for 45-60 min. at 4°C. At the end of centrifugation supernatant of the 
tubes were taken into new 1.5mL eppendorf tubes. The samples were labeled and 
stored at -20°C for short term or -80°C for longer storage. 
2.3.7 Western Blotting 
Before start a western blot, the concentration of the proteins to be used must be 
determined and quantified. For this matter, Bradford assay was used to detect the 
total protein concentrations. Dependent on the need but, usually 30-40µg of protein 
was loaded to the gel generally prepared in 20-30µL, including 20X DTT and 5X 
loading dye.  A mixture of these ingredients were prepared and put in 1.5mL 
eppendorf tubes, and consecutively placed in heater, which was pre-heated to 100°C 
and incubated for 10 min. At the end of 10 min. samples were placed on ice for 1 
min. and just before loading they were spun down for 5-10 sec.  
The concentration of a gel depended on the molecular weight of the proteins to be 
used, in this study most of the proteins had molecular weight between 50-90kDA, 
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heretofore 10-12% gels were used, though Stacking gel was 5%. The ingredients for 
10% and 12% gels were as follows:  
Solution Components 10% Gel (10mL)  12% Gel (10mL) 
ddH2O 4 mL 3.3 mL 
30% acrylamide mix 
(pH:8.8) 
3.3 mL 4 mL 
1.5M Tris (pH : 8.8) 2.5 mL 2.5 mL 
10% SDS 0.1 mL 0.1 mL 
10% Ammonuim 
persulfate 
0.1 mL 0.1 mL 
TEMED 0.01 mL 0.01 mL 
For the preparation and running procedures, Bio-Rad Mini PROTEAN Tetra Cell 
system was used. Completing the preparation of the gels, they were transferred into 
mini tank, and upon transfer, the tank was filled with 1X running buffer, after which 
the comb was removed. Previously prepared samples were loaded into gel, and the 
power-supply was connected and set to 80V until the samples escaped the stacking 
gel, then the voltage was raised to 120V until the desired time. After running, gels 
could be either dyed by Coomassie Brilliant Blue staining or they could be put in 
transfer directly. Transfer procedure, in its very essence, aimed to transfer the 
proteins stuck in gel to a PVDF or nitrocellulose based membrane for 
immunodetection. For this, a wet transfer system by using the apparatus of Bio-Rad 
Mini Transblot Cell, the transfer was performed. Complete transfer buffer contained 
1X Transfer buffer, 10-20% Methanol, and completing the rest with ddH2O. Either 
nitrocellulose or PVDF membranes were prepared as 6.5X9cm
2
, as well as Whatman 
papers. Two sponges, Whatman papers, membrane and gel were placed properly into 
the sandwich apparatus, which was then enclosed and placed into transfer tank filled 
with complete transfer buffer. Transfer was done at 100V for 90 min. Following 
transfer; Ponceau staining could be done in order to assess the efficiency of the 
transfer. Otherwise, blocking step was the next step; in which according to the 
antibody to be used the content of the blocking solution was changed. Blocking 
solution was either 5% non-fat dry milk or BSA which was dissolved in 0.2% 
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Tween-20 in TBS-T, and was performed as 1 hour at RT, though in some cases o/n 
gently shaking incubation at 4°C is also plausible. Next step was primary antibody 
incubation, for this manufacturer’s protocols were followed, and if not worked 
properly, as set of optimization experiments were performed to get the best 
conditions. After primary antibody incubation, the membranes were washed with 
0.2% Tween-20 in TBS-T as twice 5 min, 10 min and following twice 5 min. Then, 
secondary antibody incubation was performed as primary was done. Another set of 
washing steps was performed just as the previous one. Secondary antibody 
incubation was done in RT for 1 hour with gentle shaking. The last two steps were 
immunodetection of the membrane, and transfer of the signal to an X-ray film. For 
the preceding step, ECL Prime chemiluminescent detection kit was used and 
incubated for 5 min at dark, and then the membrane was hybridized with the film 
with differential time points in a dark room with X-ray developer. 
2.3.8 Immunoperoxidase Assay 
Immunoperoxidase assay was began with the fixation of the cells with 1:1 Acetone: 
Methanol fixation medium, incubated at -20°C for 10min. Next, wells were washed 
with 1X PBS for 5 min. on shaker. In order to halt the endogenous peroxidase 
activity to prevent it from interfering with the actual signal, 3%H2O2 was used and 
incubated for 10 min at dark at RT. Following incubation wells were washed with 1X 
PBS three times each for 5 min. with shaking. The latter step was blocking, blocking 
solution containing 10% FCS and 0.3% Triton X-100 in 1X PBS was put over cells 
plates were covered with stretch film and incubated at RT for 1 hour at dark. Primary 
antibody preparation was designed depending on the type of the protein as described 
in manufacturer’s protocols. Primary antibody was prepared in blocking solutions 
and 100 µL of the solution was dropped over the cover slips and incubated overnight 
at 4°C. Next day, plates were washed once with 1X PBS-t (0.3% Triton X-100), and 
secondary antibody incubation was done by putting 80 µL from Dako EnVision + 
Dual Link system – HRP for 1 hour at dark. Then wells were washed with 1X PBS-t 
(0.3% Triton X-100) twice for 2 min each. Finally, DAB solution was put over the 
slides as 80 µL and waited until the color change. Wells were washed with distilled 
H2O to stop the reaction. The last step was haematoxylin staining, which was also 
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known as counter staining. In this staining haematoxylin was put into each well and 
waited for 5min at RT, wells were washed three times with tap water. After washing 
steps were completed, slides were taken and in each, a drop of 90% glycerol was 
dripped, and coverslips were placed on these slides, then slides were visualized under 
light microscope to assess the signal. 
2.3.9 Immunofluorescence Assay 
Plates were taken out and the media was aspirated, wells washed once with 1X PBS 
for 5min with gentle shaking. 4% Formaldehyde solution was used for fixation, and 
put in wells and incubated at RT for 10 min. Wells were rinsed with distilled H2O for 
once and washed with 1X PBS for 3min on shaker. Permeabilization step was the 
following step, in which cells were washed with 1X PBS/ 0.5% Saponine/ 0.3% 
Triton X-100 solution for three times each for 5min. with shaking. Washing of the 
cells was performed by 1X PBS for 3 min on shaker. In blocking step, the blocking 
solution was prepared as a mixture of 1X PBS/ 10% FCS/ 0.3% Triton X-100, and 
this solution was applied to cells plates were incubated for 1 hour at 37°C. After 
blocking wells were washed once with PBS and incubation of primary antibodies 
was taken place according to the preferred antibody concentrations. Incubation lasted 
for 1-4 hours at RT.  Then, cell were washed with 0.3% Triton X-100 PBS three 
times for 5 min with shaking.  For secondary inbucations different fluorescently 
tagged antibodies were used such as anti-goat, anti-mouse, anti-rabbit. Secondary 
antibody incubation was done by incubating cells in dark at RT for 1 hour. Cells 
were washed three times with 0.3% Triton X-100 PBS. DAPI stain was prepared in 
distilled H2O, and cells were incubated for 1 min at dark. After DAPI staining cells 
were washed once with ddH2O.  Fluorescent mounting medium was put over slides 
and cover slips were placed over the slides. Slides must be kept at dark, and then 
could be visualized under fluorescent microscope. 
2.3.10 Flow Cytometry  
Cells were trypsinized and collected in 15mL falcon tubes, centrifuged at 1600rpm 
for 5min. Following aspiration, cells were washed twice with 1X PBS, and 
centrifuged at 1600rpm for 5min in each washing step. After aspirating PBS clearly, 
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Fixation medium A was mixed with cell pellet and vortexed for 10 sec and incubated 
at RT for 15 min. When fixation finished, cells were washed once with PBS-Na 
Azide-BSA solution in order to get rid of excess fixation medium, and were 
centrifuged at 1800rpm for 5min. Next step was the antibody incubation step in 
which fluorescent signal-tagged antibodies were prepared in PBS-BSA-Na Azide 
solution and incubated with cells for 10 min at 4°C. Then, 2mL PBS-BSA-Na Azide 
solution was added on top of the cells and centrifuged at 1800rpm for 5 min. Finally, 
the supernatant was aspirated and cells were re-suspended in 1X PBS. The prepared 
cells were finally read and analyzed by BD CSampler machine.  
2.3.11 Immunotherapy of Hepatocellular Carcinoma in Athymic mice 
Xenografts 
For tumor immunotherapy experiments of mice, Huh7 cells (5x10
6 
cells/animal in 
100ul
 
media) were injected sub-cutaneously into 20 atymic nude mice. Tumor sizes 
were followed and upon reaching around 400-500 mm
3
 combination therapy was 
initiated as shown below. Tumor nearing animals were divided into 4 treatment 
groups (see below). The injection plans were as follows: 
Subcutaneous injection: 
 Mice Group Day  -21 Day 0 
Group 1 Huh7 only PBS only 
Group 2 Huh7 only DAPT (100 ug/mice) 
Group 3 Huh7 only pI:C (100 ug) + LTA (10ug)/mice  
Group 4 Huh7 only pI:C (100 ug) + LTA (10ug)/mice  
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Peritumoral injection #1  
Mice Group Day 1 
Group 1 PBS only 
Group 2 DAPT (50ug/mice in 100 ul) 
Group 3 R848(25ug) + pI:C(50ug)+ K23(25ug) 
Group 4 R848(25ug) + pI:C(50ug)+ K23(25ug)(100ul/mice) + DAPT (50ug/mice) 
Peritumoral injection #2 
Mice Group Day 6 
Group 1 PBS only 
Group 2 DAPT (100ug/mice in 100ul) 
Group 3 R848(25ug) + pI:C(50ug)+ K23(25ug)(100ul/mice) 
Group 4 R848(25ug) + pI:C(50ug)+ K23(25ug)(mice) + DAPT (100ug/mice) 
2.3.12 Statistical Analysis 
Statistical significance between control and experimental groups was calculated 
using Student`s T- test. p<0.05 was considered as significant. 
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Chapter 3 
3. Results 
 
The aim of this thesis was to identify the CSC sub-polpulation among several 
established HCC cell lines. Our initial efforts were directed to understand the CSC 
levels as evidenced by CD133 expression. 
3.1 Investigation of CD133 Positivity Levels in Hepatocellular 
Carcinoma Cell Lines as a Biomarker 
Examination of a cell population requires a marker, to begin with, in this regard, 
since our aim was to understand the biology of CSCs in HCC, determination on a 
specific and strong marker is an essence. In this study, analyses were mostly done by 
CD133, which is a penta-span membrane protein of prominin family of proteins. As 
well as being used as one of the prime candidate stem cell markers, CD133 levels 
were investigated to assess CSC status of different type of cancers including human 
colon carcinoma, prostate tumors, pancreatic adenocarcinoma, neural tumor, renal 
tumors, and focus of this study hepatocellular carcinoma tumors 
57
. High preference 
of CD133 as a cancer stem cell marker, as well as the quality of the articles using this 
markers led us to prefer it as a way to begin our research. 
3.1.1 Panel for Basal CD133 Abundance of Hepatocellular Carcinoma Cell 
Lines 
Seventeen HCC cell lines were used in this study, some of which are known to be 
well-differentiated and some known as poorly-differentiated. These cells lines are 
HepG2, HepG2-2215, Hep3B, Hep3B-TR, Hep40, Huh7, FLC4, FOCUS, Mahlavu, 
PLC/PRF/5, SK-HEP-1, SNU182, SNU387, SNU398, SNU423, SNU499 and 
SNU475. Basal CD133 levels of these cell lines were established as a panel to pick 
up our candidate cell lines to be used in further studies. Immunoperoxidase method 
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was used for these initial screening studies, cells were seeded on cover slips in 
complete media and 48 hours later were fixed and checked for CD133 levels. The 
results of this study revealed that off 17 cell lines at hand, 11 HCC cell lines were 
found to be negative for CD133 expression, (Figure 3.1) and 6 HCC cell lines were 
found to be positive for CD133 expression (Figure 3.2).  
 
Figure 3.1: Eleven hepatocellular carcinoma cell lines that were detected to be 
negative for CD133 expression. CD133 antibody hybridized slides were stained by 
immunopreoxidase method and images were taken by brightfield microscope at 40X 
magnification. Absence of brown staining indicates low or no CD133 expression. 
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Figure 3.2: Six HCC cell lines were detected to be positive for CD133 expression. 
CD133 antibody hybridized slides were stained by immunoperoxidase method, and 
images were taken by brightfield microscope at 40X magnification. Cell lines were 
ranked based on the brown staining intensities representing increasing CD133 
positivitiy levels. 
3.1.2 Checking CD133 Positivity Panel Results by Flow Cytometry 
Having been determined the initial qualitative states of CD133 in HCC cell lines, 
presence of a potential cancer stem cell population was indicative. Yet, a quantitative 
method has to be developed before convincingly reach a conclusion. For this very 
reason, we repeated the cell line screening once again using flow cytometry method, 
which is a highly trusted and quantitative method widely used in similar studies 
50,51,53,56
. While performing the staining APC conjugated CD133 antibody was used 
as a single marker. Similar to what was done during immunoperoxidase staining, we 
repeated FACS analyses with all 17 HCC cell lines (Figures 3.3 and 3.4).  Here, we 
set a threshold for accepting a cell line positive or negative for CD133 expression. 
Any read-out that was determined to be less than 10% CD133 positivity we would 
consider that cell line as negative. 
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Figure 3.3: Representative dot plots of eleven HCC cell lines lacking CD133 
expression.  Flow cytometric analyses was conducted by using anti-CD133-APC 
conjugated antibody. 
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Figure 3.4: Representative dot plots of HCC cell lines positive for CD133 
expression. Flow cytometric analyses was conducted by using anti-CD133-APC 
conjugated antibody. 
Overall analyses with flow cytometry reproduced what we initially observed with 
immunoperoxidase staining. Here, a similar pattern was obtained, 6 cell lines, 
HepG2, HepG2-2215, PLC/PRF/5, Huh7, Hep3B-TR, Hep3B were detected to be 
positive (Figure 3.4) compared to the remaining 11 cell lines, Snu182, Snu387, 
Snu398,Snu423, Snu475, Snu449, FOCUS, FLC4, Mahlavu, SK-HEP-1 and Hep40, 
(Figure 3.3). The expression profiles of these cell lines based on CD133 positivity is 
presented on Figure 3.5.  
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Figure 3.5: Graphical representation of the flow cytometry data showing the CD133 
positivity levels of 6 HCC cell lines. Experiments were done in duplicates, and the 
results were plotted after two independent repetition results. 
3.2 Serum Starvation Model to Assess Cancer Stem Cell Sub-
Populations in Hepatocellular Carcinoma Cell lines 
Until this step, cells were grown in complete media, having all the necessary 
components for them to grow freely. Yet, in order to understand the true nature and 
level of existing CSCs within the HCC population and to enrich the ones that are 
CSCs, we adapted a stress condition  onto these cells. After three days in complete 
media, we cultured these cells in serum starvation media. The ultimate logic behind 
this approach was the following, non-CSC cells need nutrients in order to continue to 
grow in the culture dish, and if the supplement was discontinued, they will enter 
apoptosis, yet the cells that have the potential of being CSC remain alive because of 
their resistance to harsh conditions. Therefore, this model was chosen to force the 
CSCs to be the sole survivors, and eliminate the ones that are less stem-like. 
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3.2.1 Effects of Serum Starvation on CD133+/EpCAM+ Cancer Stem Cell 
Population  
Having a marker, CD133, was an acceptable approach to assess CSCs, yet in similar 
studies it is more convincing to include another marker. We chose to include another 
common CSC marker, EpCAM for these studies. For the rest of the study, double 
staining protocol will be employed to designate CSC sub-populations.  
To confirm that we do detect correct CSCs in our analyses, three cell lines, one with 
low CSC population (HepG2), one with a medium CSC level (Huh7), and  one from 
high-expresser candidate cell lines (Hep3B-TR) were chosen. To begin with, the 
basal CD133/EpCAM double positive subpopulations in these three cell lines were 
detected (Figure 3.6). Following that adjustment, cells were seeded in parallel plates 
and at Day 1, they were fixed, stained with FITC conjugated EpCAM antibody and 
APC conjugated CD133 antibody, and analyzed by flow cytometry. On the parallel 
plates, cell were kept at complete media for 72hours and changed to serum starved 
media, and left in serum starved media for 72 hours as well, then cells were 
collected, fixed, stained and analyzed with flow cytometry to detect any substantial 
variances (Figure 3.6).    
Upon analysis of the results, CD133
+
/EpCAM
+ 
sub-population in HepG2 shows a 
25% shift when left in serum starved media for 72 hours (Figure 3.6). A resembling 
increase was also seen in Huh7, nearly 23% increase in  CD133
+
/EpCAM
+ 
cells was 
detected (Figure 3.6). Conversely, in case with Hep3B-TR, a sister cell line Hep3B 
but desensitized form that does not respond to TGF-β1, no significant change in 
CD133
+
/EpCAM
+ 
sub-population levels were assessed (Figure 3.6).    
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Figure 3.6: Effects of serum starvation on CD133
+
/EpCAM
+ 
subpopulation of CSCs 
in selected HCC cell lines. D3 represents cells incubated for 3 days in complete  
media whereas D6 represent cells incubated in starvation media for 3 days. 
3.2.2 Time-dependent alteration of CD133+/EpCAM+ Cancer Stem Cell 
Fraction in Serum Starvation 
Experiments with 72 hours starvation led us to dissect this phenomenon in greater 
detail. There was an apparent change, yet how this trend shifted over time needed 
extra evaluation. To focus more on time dependency, daily differences in 
CD133
+
/EpCAM
+ 
sub-population within first 72 hours in complete media was 
checked. Cells were plated and parallel plates were designed and fixed at 24 hours, 
48 hours and/or 72 hours after seeding. Fixed cells were stained and analyzed by 
flow cytometry to assess CD133
+
/EpCAM
+ 
CSC populations. Analyses for the first 
72 hours in complete media revealed that there was no significant change in the 
CD133
+
/EpCAM
+ 
subpopulations as expected (Figure 3.7). 
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Figure 3.7: Dot plots showing the time-course change in CD133
+
/EpCAM
+
 
subpopulation within three  different HCC cell lines. D# represents incubation 
number of  days in complete  media. 
Next, three different cell lines expressing low (HepG2), medium (Huh7) and high 
(Hep3B-TR) CD133
+
/EpCAM
+
 were subjected to serum starvation for 72 hours, 
following 72 hours incubation in complete media. As done previously, cells were 
fixed and checked at different time points 24 hour, 48 hour or 72 hour serum 
deprivation for any shifts in CD133
+
/EpCAM
+ 
levels to determine the time course 
effect of serum deprivation on CD133
+
/EpCAM
+ 
subpopulation (Figures 3.8-3.10).  
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Figure 3.8: Flow cytometry analyses showing the daily changes occuring in 
CD133
+
/EpCAM
+
 subpopulation within serum deprived media for HepG2. For the 
top row D# indicates the number of days spent in complete media, for the bottom row 
D4 serum starvation represents 3 days in complete media plus 1 day in serum 
starved media, for D5 2 days in serum starved media and D6 3 days in serum starved 
media. 
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Figure 3.9: Flow cytometry analyses showing the daily changes occuring in 
CD133
+
/EpCAM
+
 subpopulation within serum deprived media for Huh7. For the top 
row D# indicates the number of days spent in complete media, for the bottom row D4 
serum starvation represents 3 days in complete media plus 1 day in serum starved 
media, for D5 2 days in serum starved media and D6 3 days in serum starved media. 
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Figure 3.10: Flow cytometry analyses showing the daily changes occurring in 
CD133
+
/EpCAM
+
 subpopulation within serum deprived media for Hep3B-TR. For 
the top row D# indicates the number of days spent in complete media, for the bottom 
row D4 serum starvation represents 3 days in complete media plus 1 day in serum 
starved media, for D5 2 days in serum starved media and D6 3 days in serum starved 
media. 
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Figure 3.11: Graphical representation of the changes occurring in 
CD133
+
/EpCAM
+ 
subpopulation on a daily basis for 6 days in three different HCC 
cell lines. Experiments were done in duplicates, and the results were plotted after 
two independent repetition results. 
Upon comparison of the effect of time spent in complete media on CD133
+
/EpCAM
+ 
fraction, different trends of the cell lines can be detected. For HepG2 and Huh7, there 
seems to be a gradual drop in CD133
+
/EpCAM
+
 population levels after Day 3, same 
is true for Huh7 as well, yet Hep3B-TR acts through a completely different response, 
almost no shifts in CD133
+
/EpCAM
+
 population level (compare Figures 3.9-3.11 and 
3.12). 
Exposure to serum starved media exerts its effects in favor of CD133
+
/EpCAM
+
 
population in both HepG2 and Huh7, from Day4 until Day 6. However, no 
significant change in Hep3B-TR was observed in response to serum deprivation 
(Figure 3.12). 
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Figure 3.12: Graphical representation of the changes occurring in 
CD133
+
/EpCAM
+ 
subpopulation on a daily basis in serum starvation for 3 days in 
three different HCC cell lines. Experiments were done in duplicates, and the results 
were plotted after two independent repetition results. 
Analyses of all three cell lines revealed that CD133
+
/EpCAM
+ 
population is affected 
by serum starvation and levels were increased in both HepG2 and Huh7 on a daily 
basis, but not in Hep3B-TR (Figure 3.13-3.15). 
 
Figure 3.13: Graphical representation of the changes occurring in 
CD133
+
/EpCAM
+ 
subpopulation in complete vs. serum-starved media for HepG2. 
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Figure 3.14: Graphical representation of the changes occurring in 
CD133
+
/EpCAM
+ 
subpopulation in complete vs. serum starved media for Huh7. 
 
Figure 3.15: Graphical representation of lack of the changes occurring in 
CD133
+
/EpCAM
+ 
subpopulation in complete vs. serum starved media for Hep3B-TR. 
Taken together, our findings revealed that HepG2 and Huh7 CSC levels rose by ~2x 
when incubated in serum starved condition (for 3 days) compared to complete media 
incubation. As expected, Hep3B-TR did not display any alteration in CSC positivity 
irrespective of stress condition.  
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3.3 Notch Signaling Involvement in Regulation of Cancer Stem Cell 
Population in Hepatocellular Carcinoma 
Notch signaling pathway is one of the fundamental pathways necessary during 
embryogenesis, development and adulthood in maintenance of stemness, regulation 
of differentiation and fate switching 
81,83,101
. In immature mice hepatocytes, Notch 
activation triggers switch from hepatocytes to an oval cell like structure and then to 
biliary epithelial cells (BECs) 
101
. It is known to be deregulated in numerous cancer 
types. Notch activation was found to be leading to an increase in mammosphere 
formation, and also reported to trigger angiogenesis during solid tumor formation 
83
. 
Therefore, Notch signaling pathway is one of the prime candidates to be responsible 
to regulate in CSC reprogramming which is the very reason to be investigated in this 
study, as well.  
3.3.1 Altered Notch Signaling Affects CD133+ Cancer Stem Cell Fraction in 
Huh7 
To unravel the role of Notch in CSC population, effects of inhibition as well as 
activation of the pathway was tried. The contribution of Notch on CD133+ sub-
population of HCC cell lines was surveyed. Jagged-1 is a soluble ligand that is 
specific for Notch-1 receptor, and leads to activation of Notch signaling. DAPT (N-
[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), on the other 
hand, is a gamma-secretase inhibitor and block the presenilin complex activity, 
which is naturally in charge of NICD cleavage. Having been blocked by DAPT, 
gamma-secretase complex cannot work on NICD, therefore release of NICD cannot 
occur, which will render Notch signaling to be inactive. In this part of the work, 
Jagged-1 and DAPT was used to understand the effects of Notch 
interruption/activation on CD133
+
 CSC population.  
For the initial experiments, cells were plated in very diluted amounts to form 
colonies so that they could be forced into a clonal expansion, and at this state we 
could observe any changes during colony formation. Cells were left in complete 
medium for 72 hours and at the end of this duration, medium was changed to serum 
starved media and cells were treated with either DAPT or Jagged-1 (3.16).  
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Figure 3.16: Immunoperoxidase assay results showing colony formation experiment 
with Notch agonists and antagonist to understand their effects CD133 positivity. 
Cells were stained with anti-CD133 antibody as primary Ab, DAKO Envision + 
system was used for HRP-conjugated secondary Ab incubation. 
Immunoperoxidase experiment results were chosen to be representative images that 
are in accordance with the results seen in Figure 3.16. Jagged-1 treatment leads to a 
two-fold  increase in the levels of CD133 positive colony count. Yet DAPT is 
responsible for a drop in the number of CD133 positive colony counts. DMSO seems 
to be having no effect at all (Figure 3.16, Figure 3.14).  
 
Figure 3.17: Quantitative representation of the colonies having CD133 expression 
higher than 20% within themselves upon Notch ligand and inhibitor treatment of 
Huh7 cells. Statistical analysis was done by Student's t-test and *p <0.05 between 
DAPT and control - Jagged-1 and control. 
  
73 
3.3.2 Dose-dependent Effects of Notch Alteration on CD133+/EpCAM+ Cancer 
Stem Cell Population 
Through confirmation of differential Notch effect on CD133 positivity of Huh7 CSC 
sup-population from Figure 3.17, we next aimed to understand the effective 
concentrations of Jagged-1 and DAPT to eliminate any toxic effects on the cells. In 
order to do so, the cell lines were treated with different doses of Jagged-1 as 2ng/ml, 
10ng/ml and 50ng/ml and with DAPT 6.6µM, 20µM and 60µM respectively. Cells 
were first plated and left in complete media for 3 days and at day 4 replaced with 
serum-free media supplemented either with Notch ligand or the inhibitor DAPT, and 
analyzed at day6 by flow cytometry. Instead of single staining this time a double 
staining with CD133 and EpCAM was performed.  
Analyses of the data related to dose-dependent Notch related treatment of the cells 
yielded slightly different outcome compared to what was seen during 
immunoperoxidase data (compare 3.17 with 3.18-3.20). Jagged-1 does not seem to 
be having a positive effect on CD133
+
/EpCAM
+ 
population also the p-value between 
Jagged-1 treatment and untreated samples was non-significant (p> 0.05) (Figure 
3.18, and Figure 3.19). In case for Hep3B-TR no Jagged-1 induction was used since 
it does already have a quite high percentage of CD133
+
/EpCAM
+ 
cells. The most 
important data, in these set of experiments, was obtained from DAPT treatments 
(Figure 3.18, Figure 3.19 and Figure 3.20). Both in HepG2 and Huh7, DAPT 
treatment seems to be downregulating CD133
+
/EpCAM
+ 
population as 60% and 
50%, respectively. However, again, DAPT does not necessarily alter 
CD133
+
/EpCAM
+ 
fraction in Hep3B-TR (Figure 3.21). Hep3B results can be found 
at Appendix A1.    
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Figure 3.18: Dot-plot analyses showing the dose-dependent effects of Jagged-1 and 
DAPT on CD133
+
/EpCAM
+
 subpopulation shifts in HepG2 at day 6. 
 
Figure 3.19: Flow cytometry analyses showing the dose-dependent effects of Jagged-
1 and DAPT on CD133
+
/EpCAM
+
 subpopulation shifts in Huh7. 
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Figure 3.20: Flow cytometry analyses showing the dose-dependent effects of Jagged-
1 and DAPT on CD133
+
/EpCAM
+
 subpopulation shifts in Hep3B-TR. 
When this set of findings are taken together, it is fair to conclude that while the 
positive effect of Jagged-1 on CSC upregulation is inconclusive, DAPT tretment 
leads to significant reduction of CSC sup-population in HepG2 and Huh7 (Figure 
3.21). This finding is critical for developing an effective immunotherapeutic 
approach against certain HCC conditions. It deserves to test the validity with 
xenograft experiments in athymic mice. 
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Figure 3.21: Graphical representation showing the effects of Jagged-1 and DAPT on 
CD133
+
/EpCAM
+
 subpopulation shifts in HepG2, Huh7 and Hep3B-TR. Results 
were analyzed by Student's t-test and p-values for both HepG2 and Huh7 p<0.05. 
3.3.3 Time-dependent Effects of Notch Alteration on CD133+/EpCAM+ Cancer 
Stem Cell Population 
Previous experiments demonstrated that there is a reduction of CD133
+
/EpCAM
+ 
population by DAPT treatment, but at 50 ng/ml Jagged-1 there was no improvement 
in CD133
+
/EpCAM
+ 
. In the first set of experiments samples from 72 hours serum 
starvation were checked. To assess at time-dependent changes of CSC sup-
population by DAPT, and Jagged (with higher doses though) cells were collected and 
analyzed at 24 hours, 48 hours and 72 hours after 60 µM DAPT treatments (Figures 
3.22-25). In these set of experiments while we increased  Jagged-1 from 50 to 200 
ng/ml, we kept  DAPT at 60 µM. 
As seen in the following Figures, Jagged-1 even at 200 ng/ml had no positive effect 
on CD133
+
/EpCAM
+ sup-
populations of the tested cell lines. Similar to previous 
observations DAPT treatment reduced CSC level by ~ 2X for all the cell lines tested 
over the course of three days. The only exception that DAPT was ineffective was on 
Hep3B-TR (Figure 3.24, 3.25). 
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Figure 3.22: Flow cytometry analyses showing the time dependent changes of 
CD133+/EpCAM+ fraction upon DAPT and Jagged-1 treatments in HepG2. 
 
Figure 3.23: Flow cytometry analyses showing the time dependent changes of 
CD133+/EpCAM+ fraction upon DAPT and Jagged-1 treatments in Huh7. 
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Figure 3.24: Flow cytometry analyses showing the time dependent changes of 
CD133+/EpCAM+ fraction upon DAPT and Jagged-1 treatments in Hep3B-TR. 
 
Figure 3.25: Effects of DAPT on CD133+/EpCAM+ population in a time-dependent 
manner.  
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As we have mentioned earlier, Hep3B-TR, is a desensitized for TGFB1 receptor 
expression. The findings presented in Figure 3.24 are not unexpected, since 
inhibition of Notch by DAPT will have little or no effect on TGFB1 receptor levels.   
3.4 Investigation of Oval Cell-like Population in Hepatocellular 
Carcinoma Cell Lines 
Oval cells are named also as the stem cells of the liver, in case of an injury this 
population of cells, since possessing a bipotential character, differentiates into 
hepatocytes or cholangiocytes (cells forming the bile ducts), which are the two major 
types of epithelial cells resident in the liver 
102
. There are studies showing that upon 
Notch signaling activation in new born mice, immature hepatocytes go through a fate 
switch and differentiates into biliary epithelial cells 
101
. In another study, it was 
shown that HNF4α+ hepatocytes in adult mice liver upon ectopic Notch activation or 
during biliary injury undergoes a fate switch and become HNF4α+ / SOX9+ 
hepatocytes. Later these cells assume a following switch and become only SOX9+ 
cells. These intermediate bi-phenotypic stage cells show morphological and marker-
based characteristics of oval cells 
103
.   
In this part of the study it was hypothesized that, since Notch signaling activation 
seems to be interfering with CSCs, and this bi-phenotypic cells resemble oval cells, 
presence of these double positive cells could be included as a contaminant in our 
CSC sup-population. In order to check this hypothesis, HNF4α and SOX9 protein 
levels in the cell lines previously detected to be positive for CD133 expression was 
examined. Western blot analysis was done in 6 HCC cell lines positive for CD133, 
these were HepG2, HepG2-2215, Hep3B, Hep3B-TR, Huh7 and PLC. A CD133 
negative cell line FLC4, was also used to assess the HNF4α+/Sox9+ status (Figure 
3.26). 
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Figure 3.26: Western blot analysis images showing the heterogeneous expression of 
HNF4α+ and Sox9+ oval cell markers in HCC cell lines. 
After the western blot of CD133 expressing cell lines, 5 HCC cell lines (HepG2, 
HepG2-2215, Hep3B, Hep3B-TR) were detected to be expressing both HNF4α and 
SOX9. Detection of co-expression of these markers has evoked the question of 
whether this expression is present within individual cells, since presence of such cells 
will be a sign of potent stem cell or oval-like cells in a cancer cell line. This may 
further relate to the biology of CSCs, in terms of their resemblance of oval-like cells. 
Immunofluorescence analyses was done to further both confirm the results from 
western blot analyses and in order to point out individual cells showing a HNF4α+ 
and/or SOX9+ phenotype (Figure 3.27-3.30). 
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Figure 3.27: Immunofluorescence images showing presence of co-expression of 
HNF4α and SOX9 in HepG2 and HepG2-2215 cell lines. Antibodies were Sox9-
Alexa 488 and HNF4α-Alexa 568. 
 
Figure 3.28: Immunofluorescence images showing presence of co-expression of 
HNF4α and SOX9 in Hep3B and Hep3B-TR cell lines. Antibodies were Sox9-Alexa 
488 and HNF4α-Alexa 568. 
 
 
Figure 3.29: Immunofluorescence images showing presence of co-expression of 
HNF4α and SOX9 in Huh7 and PLC cell lines. Antibodies were Sox9-Alexa 488 and 
HNF4α-Alexa 568. 
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Figure 3.30: Immunofluorescence images showing absence of co-expression of 
HNF4α and SOX9 in FLC4. Antibodies were Sox9-Alexa 488 and HNF4α-Alexa 568. 
After immunofluorsence analysis of these different HCC cell lines, we detected that 
both HNF4α+/Sox9 + double positive cells co-existed within CD133+/EpCAM+ cell 
sup-populations.  These intriguing results suggests the following possibilities. i) 
These markers could be used to identify potential CSC sub-populations in a cell line. 
ii) These cells couls attain these extra markers and comprises what was known as an 
oval cell. Further analysis, needs to be done to analyze these possibilities in the 
future. The regulatory role of Notch signaling on these marker expressions also 
deserves detailed investigation.  
3.5 Determination of Toll-like Receptor Activity in Hepatocellular 
Carcinoma 
Lately, tumor microenvironment and cancer-immunotherapy has become hotter 
topics. Usage of TLRs as a way of cancer-immunotherapy was applied for a while 
now. However, TLR therapy on HCC was not a topic worked on very often 
previously. Yet, in order to construct a hypothesis, our team went through a 
screening set of experiments to detect the presence of TLR expressions if any.  
3.5.1 Basal Toll-like Receptor Expression in Hepatocellular Carcinoma Cell 
Lines 
To assess the basal TLR levels in 6 HCC cell lines, which were found to be positive 
for CSC markers CD133 and EpCAM in variable percentages. A PCR based analysis 
method was used for this cells were seeded and left overnight, next day cells were 
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collected, total RNA was isolated and cDNA was synthesized. PCR was then 
performed to construct a panel for TLRs in HCC.  
As seen from Figure 3.30, there is a differential TLR expression in different cell 
lines, yet most of them express TLR5. HepG2 seems to have TLR4, TLR5 and TLR6 
expression, yet HepG2-2215 has TLR4 and TLR5 expression. 
 
Figure 3.31: Gel image showing PCR product bands for basal TLR levels in 6 HCC 
cell lines. Red box: upregulation. 
 
Huh7 shelters only TLR5 expression, whereas, Hep3B has TLR5 and TLR6 
expression. Hep3B-TR has only TLR5 expression but PLC has TLR5, TLR6 and a 
very slight TLR10 expression. 6 hour LPS treated PBMCs and 6hour R848 treated 
PBMC RNAs were used as positive controls. 
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3.5.2 Effects of TLR ligand treatments on the expression levels of TLRs in HCC 
cell lines.  
In this part, we aimed for inducing the TLR receptors by using different TLR 
ligands, including lipoteichoic acid (LTA), peptidoglycan (PGN), lipopolysaccharide 
(LPS), polyinosinic: polycytidilic acid (Poly(I:C)), flagellin, R848, resiquimod and 
K23 on different HCC cell lines. Cells were seeded the day before, and settled 
overnight, next day, cells were induced by different concentrations of TLR ligands, 
after 4 hours of induction total RNA was isolated from the cultured cells. These 
analyses were conducted on 4 cell lines HepG2, Huh7, Hep3B, and Hep3B-TR. 
Hep3B results can be found in Appendix A2. 
For HepG2 compared to the untreated group, LTA, PGN, LPS, poly(I:C), R848 and 
K23 seem to be upregulation of TLR5, only PGN causes a slight increase in TLR6 
levels. LTA, PGN, LPS and K23 increase TLR7 levels, and TLR8 is induced by 
LTA, PGN and K23. TLR9 is only induced by K23, whereas TLR10 upregulated by 
induction of LTA, PGN, poly (I:C), flagellin, R848 and K23 (Figure 3.32).  
 
Figure 3.32: Gel image showing PCR product bands of TLR levels in HepG2 upon 
under treatment of different TLR ligands. Red box: upregulation. 
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For Huh7 expression changes, TLR5 is induced by LTA, LPS and especially 
upregulated by Poly (I:C), but down-regulated by flagellin.  There seems to be an 
effect of Resiquimod on TLR7 induction but actual impact comes from K23. TLR10 
is induced by K23, as well (Figure 3.33). 
 
Figure 3.33: Gel image showing PCR product bands of TLR levels in Huh7 upon 
treatment with different TLR ligands. Red box: upregulation, green box: down 
regulation. 
For Hep3B-TR, LTA leads to a strong induction in TLR2 levels, as well as TLR4. 
PGN, LPS and Poly(I:C) cause a decrease in TLR4 levels. TLR5 levels, this time 
surprisingly lowered by LTA, LPS, Poly(I:C), flagellin and K23 induction. TLR was 
induced by LPS. TLR10 signal was lowered by LTA, Poly(I:C) and R848, but was 
increased by LPS, Resiquimod and K23 induction (Figure 3.34). 
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Figure 3.34: Gel image showing PCR product bands of TLR levels in Hep3B-TR 
upon treatment with different TLR ligands. Red box: upregulation, green box: down 
regulation. 
3.6 Strategies for effective Immunotherapy of Hepatocellular 
Carcinoma in Athymic mice Xenografts 
For the immunotherapy for Huh7 mediated established HCC in nude mice, following 
large tumor formation different treatment strategies were conducted for each group.  
It is important to note that only two injections (6 days apart) were performed during 
immunotherapy.  
We hypothesized that TLR ligands mediated immune activation plus Notch inhibitor 
effect will induce a synergistic and combined tumor cell elimination from these mice. 
As seen in Figures 3. 34 and 3.35, inclusion of both therapeutic agents in Group #4, 
reduced tumor burden up to 87.5 % (Group #1 average volume: 2650±1350 mm3 vs 
Group #4 average volume: 330±357mm3) at the end of day 9 post treatment. 
Although Group #2 and Group #3 substantially reduced tumor burden, their 
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combination induced more pronounced tumor clearance (compare Groups #2 vs #3 
vs #4; 397±223 mm3 vs 730±710 mm3 vs 330±357 mm3, respectively). 
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Figure 3.35: HCC bearing mice (N=4) tumor burden plots. Animals were 
xenotransplanted  with 4x10
6
 Huh7 cells, tumor formation was followed until they 
reached 300-400mm
3 
in size and peritumoral injections of the indicated treatments 
were done on day 1 and days 6. Tumor volumes were followed by daily 
measurements(TLRL: TLR3, TLR7, and TLR9 ligand combinations; DAPT: a 
gamma-secretase inhibitor). 
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Figure 3.36: Photomicrographs showing tumors of different mice at day 9 post 
therapy. 
 
Figure 3.37: Time course tumor growth kinetics of untreated and immunotherapy 
applied test groups.  
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Chapter 4 
4. DISCUSSION 
There were several questions to tackle throughout this thesis. First, we wanted to 
differentiate the CSC subpopulation rates among HCC cell lines upon incubating 
them in sustained stress conditions. Furthermore, another aim was to identify the 
effect of Notch signaling modulation and its effect on CSC alteration. Within the 
scope of this thesis was to develop an approach that would help to eradicate 
established large HCC tumors in athymic mice. For that, we wanted to take 
advantage of TLR signaling along with CSC reduction mechanism. In the lights of 
our observation, we achieved this by using sequential administration of several TLR 
ligands along with a Notch inhibitor, namely DAPT.  Eventually, our in vivo data 
revealed that coupling a notch inhibitor along with nucleic acid TLR sensors (i.e. 
TLR3, TLR7/8 and TLR9) synergistically contribute to eliminate HCC tumors in 
mice even after just two injections six days apart.  
4.1 Investigation of cancer stem cell subpopulation in hepatocellular 
carcinoma cell lines. 
Cancer stem cells possess self-renewal ability as well as giving rise to differentiated 
progeny of cells as normal stem cells. Chemotherapy and radiotherapy resistant 
nature of cancer, and recurrences after surgical removal, or even metastatic capability 
of a tumor are suggested to be orchestrated by CSCs 
47
. Different cancer tumor types 
were shown to be expressing intersecting markers with others or sometimes specific 
markers for themselves 
104
. Leukemia-initiating cells were, CD34
+
/CD38
-
, whereas 
breast cancer initiating cells were CD44
+
/CD24
-/low
. In determination of cancer stem 
cells in HCC, there were several cardinal markers as listed in Table 1.1. Two of these 
markers, however, were highly preferred, by many investigators working on this 
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topic, these are; CD133 (Prominin-1) and EpCAM 
56,57,61,63,67,69
. Hepatocellular 
carcinoma is the most commonly seen subtype of HCC with 80%, and is known to be 
highly resistant to chemo-and-radio therapy. Several studies demonstrated the 
existence of CSC in HCC 
53,69
. Therefore, in addition to already existing therapies it 
is critical to understand CSC involvement and offer better targeting strategies 
therapeutically. Following CSC screening of 17 HCC derived cell lines either by 
flow cytometry or immunoperoxidase analyses (Figure 3.1-3.4), we established that 6 
cell lines (35%) were positive for CD133+/EpCAM+ expression.  
Following initial determination of CD133
+ 
subpopulation bearing HCC derived cell 
lines, next step was to strengthen these outcomes with a second CSC marker, 
EpCAM. We selected 3 cell lines to work thoroughly for the rest of the study. One 
with low-CD133
+
/EpCAM
+
 subpopulation (HepG2), another with mediocre  level of 
CD133
+
/EpCAM
+ 
(Huh7), and the last one with highest CD133
+
/EpCAM
+ 
subpopulation level (Hep3B-TR) (Figure 3.6). Correlation between CD133
+
. Cancer 
cells, normally do need nutrients from the environment to grow on, in the absence of 
nutrient supplement they start dying, however, stem cells are more resistant to harsh 
conditions than differentiated cancer cells. By assuming a similar role for CSCs, we 
have applied varying serum starvation experiments for our selected cell lines.  
Initially, cells were seeded and left in complete media for three day, and then 
changed into serum starved media for another 3 days. At the end of the sixth day, 
there was around 20% increase in CD133
+
/EpCAM
+
 subpopulation in both HepG2 
and Huh7, but that was not the case for Hep3B-TR, which is desensitized for TGF-
beta-1 receptor (Figure 3.6). Yet, also, the reason for no increase is that Hep3B-TR 
already has around 96%  CD133
+
/EpCAM
+
 subpopulation, therefore, additional 
markers might be used to further analyze the shifts occurring in this cell line upon 
serum starvation. An expression analysis study between the 3rd day in complete 
media vs. 3rd day in serum starved media might give enlightening results on the set 
of genes regulating this increase in stemness to launch an idea.   
Daily follow up of the CD133
+
/EpCAM
+ 
levels in selected cell lines did not show 
any difference during first three days in complete media (Figure 3.7). However, 
when the results were inspected at day 4, day 5 and day 6 all of which were in serum 
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free media, we have detected a gradual increase, which was finalized around 40% 
increase in CD133
+
/EpCAM
+
 subpopulation in HepG2, and furthermore detected 
around 20% increase in Huh7 levels.  
4.2 Effects of Notch signaling pathway on CD133
+
/EpCAM
+
 
subpopulation in selected HCC derived cell lines 
Notch signaling pathway is one of the key signaling pathways during development. It 
is involved in stemness maintenance in embryonic stages, differentiation and fate 
decision control, as well as angiogenesis during development 
64,80,82
. Aberrations in 
Notch signaling was detected in cancer stem cells of numerous cancer types 
including breast cancer, leukemia, brain tumors and glioma 
105
. However, 
information on how Notch signaling acts on CSCs of HCC or on anti-tumoral effects 
of Notch signaling inhibition is not clear and needs further investigation. In this 
study to understand the effects of Notch signaling, a selected cell line, Huh7 was 
treated with definite Jagged-1 and DAPT concentrations to see the changes in 
CD133
+ 
population. Because of this colony formation assay, colonies with 20% 
CD133 positivity was increased by two fold in Jagged-1 treated cells, whereas upon 
DAPT treatment CD133 positivity levels of the colonies were decreased by half. 
These results may suggest a potential role of Notch signaling in the regulation of 
CD133
+
 CSC subpopulation in Huh7. Yet, this is only qualitative observation. To 
interrogate the data further, three of the selected cell lines were treated with Jagged-1 
and DAPT at varying concentrations with serum starvation. After three days in 
complete media and three days in serum starved media with treatments, a significant 
decrease (by half) in CD133
+
/EpCAM
+ 
subpopulation subpopulation was detected in 
HepG2 and Huh7 upon DAPT(60µM) treatment. However, with Jagged-1 treatment 
no significant changes were observed. These results may refer a potential role for 
Notch signaling effect on CD133
+
/EpCAM
+ 
subpopulation, yet downstream 
molecules of Notch signaling needs further investigation to further understand the 
detailed mechanism. A study has shown that in colon cancer model EpCAM 
cleavage by gamma-secretase (PS2), which coordinates S3 cleavage of NICD, along 
with TACE, coordinating S2 cleavage of Notch. After that intracellular domain of 
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EpCAM, EpICD, translocates into the nucleus where it binds to beta-catenin to 
activate cell proliferation 
106
. Such a discrepancy was not investigated in HCC 
before, therefore, Notch or signaling elements might be somehow involved in the 
regulation of EpCAM, our data supports that it does decrease the CD133
+
/EpCAM
+ 
subpopulation. This needs to be further investigated.  
Previously, it is known that in immature mice Notch signaling activation promotes 
the conversion of HNF4-alpha positive hepatocytes into biliary epithelial cells that 
are lining the bile ducts and biliary tree 
101
. Recently, the study of Yanger et al. 
suggested that upon toxic substance damage or ectopic Notch activation in the liver 
of mature mice, HNF4-alpha positive hepatocytes were directed into a 
reprogramming process, in which they were turned into HNF4α+/Sox9+ cells that 
resemble the features of oval cells, which were known to be the stem cells of the 
liver 
103
. This phenomenon led us to question the probability of the presence of such 
a population in HCC derived cell lines, especially the ones that are 
CD133
+
/EpCAM
+
. Initial screening was done by western blot, and apart from FLC4 
and PLC, all the other 5 cell lines were found to be positive for both HNF4α and 
Sox9 (Figure 3.25). These results were extremely surprising for us because this 
suggest the probability of oval cells being the source of somehow involved at an 
intermediate step through reprogramming into CSCs. To further make sure that 
individual cells co-express these two markers, we have performed 
immunofluorescence analysis, and the results were as expected, individual cells in 5 
cell lines, Hep3B, Hep3B-TR, HepG2, HepG2-2215 and Huh7 were HNF4α+/Sox9+,  
but PLC showed only mild Sox9 co-expression with HNF4α, which could be 
expected since very-low expression of proteins may not be detected by western 
blotting. FLC4 was negative for both HNF4α and Sox9 (Figure 3.26-3.29). These 
results, however, need further support to show the co-expression of HNF4α and Sox9 
with CD133 and EpCAM, as well. Moreover, the biological precedence of the 
markers should be settled down to understand whether these cells become first 
HNF4α+/Sox9+, then CD133+/EpCAM+ or vice versa. This will make us to reach 
one-step further in understanding the biological origins of liver cancer stem cells.  
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4.3 TLR expression in HCC and cancer-immunotherapy by TLR 
ligands and Notch inhibition 
Tumor cells surprisingly have developed themselves to create an immune 
suppressive environment. They do this by mediating parallel actions such as 
secretion of TGF-β, adenosine or VEGF-A. Some of these molecules lead to 
dendritic cell suppression, and some inhibit T-cell penetration into the tumor bed. In 
case of hypoxia, for instance, tumor cells secrete adenosine, which will trigger T-cell 
activation suppression 
98
. There are several approaches to overcome this 
immunosuppressive environment of the tumor bed, one of which is to make use of 
the immunostimulatory effects of toll-like receptor activation through TLR ligands. 
In this model, we use nude mice whose ultimate deficiency in tumor therapy is the 
lack of cytotoxic (CD8+) T cells (CTLs), which specifically target tumor cells. In 
nude mice' however, the major group of cells responsible for the defense against 
tumors are natural killer cells (NK cells). Previous usage of TLR agonists in HCC 
tumor in nude mice was done in only a couple of studies, which were not resulted in 
very efficient tumor shrinkage, unfortunately. Moreover, there were no hits detected 
upon TLR agonist therapy in combination with Notch inhibitor DAPT. There were 
studies showing that upon ectopic activation of NK cells which constitutively 
produce and respond to IFN-alpha, they become more activated in an efficient way to 
attack on tumor cells in nude mice 
107
. An in vitro study on TLR3 agonist treatment 
in HCC has shown that, upon dsRNA treatment to activate TLR3 in HCC cell lines, 
cells were shown to be entering into apoptosis, migration abilities were inhibited 
108
. 
Throughout the last part of this study, we have detected upregulation of four TLRs 
mainly in Huh7, TLR5, TLR7 and TLR9 and TLR10. Yet, in this study since 
involvement of TLR3 was also shown before, we have used TLR agonists for TLR3, 
TLR7 and TLR9. Along with their immunostimulatory effects by combining this 
therapy with DAPT, it was aimed to both strengthen the immune attack on tumor 
cells as well as eradicating the CSC population to prevent any follow-up 
recurrences. The combination therapy treated mice shown the highest success, 
although DAPT alone and combination therapy resulted in similar reduction in tumor 
sizes, tumors treated with only DAPT started to rebound, whereas combination 
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therapy applied mice tumors were still stable in volumes. Such an effect may imply 
that two-hit method we developed result in better response against tumor relapse 
(Figure 3.37). 
There are still some further research must be done in order to understand the 
involvement of CSCs in HCC initiation, progression, maintenance or therapy. To 
begin with, the immune cells infiltrated into tumor or the periphery must be 
controlled to determine activity of the NK cells and macrophages (in nude mice) 
compared to the immunosuppressive activity of myeloid derived suppressor cells 
(MDSCs). The aim in study is to come up with a therapy method at the end, to 
eradicate the tumor or to keep the tumor size under control, and for such a case the 
toxic effects of DAPT on non-target cells must be cleared to prevent any cytotoxic 
effects.  
Regarding to oval cells, further studies are needed done to be able to gain more 
insight into whether oval-like cells are responsible for the programming of CSCs, 
since they are in a progenitor cell state, their upcoming de-differentiation following 
genetic mutations might be leading to the  CD133
+
/EpCAM
+ 
CSC subpopulation or 
vice versa.  
In order to extend the amount of the impact of the combination therapy in reduction 
of the HCC tumors, experiments to check any connection between Notch signaling 
pathway and TLRs must be investigated. In case of the existence of any relation, 
depending on the pattern of relation, a therapy alternative to abusing this relation 
may be administered.  
Apart from starting with large tumor sizes, another challenge in this in vivo study 
was the usage of athymic nude mice. Although having its innate immune cells such a 
NK cells or macrophages, tumors shrinkages were increased upon treatment with the 
TLR ligands only. Yet, in the real life scenario, patients will have intact immune 
system, and within the adaptive immune system, CD8+ cytotoxic T cells are 
especially involved in targeting of the tumors cells as a defense mechanism. 
Therefore, repeating these tumor formation and combination therapy experiments is a 
necessity within mice having intact immune system, this way, reduction in the tumor 
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sizes may increase, or even the tumor may be completely eradicated. As final 
remark, DAPT should be administered in other cancer types (e.g. breast cancer)to 
discover it's any potential inhibition in cancer immunotherapy.  
5.  
6.  
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8. Appendices 
Appendix A 
Appendix A1 Cancer stem cell studies on Hep3B 
Serum starvation effects were also investigated on Hep3B cell lines, and it was 
detected that at the end of 72 hour serum starvation, CD133
+
/EpCAM
+
 population 
was not affected by serum deprivation (Figure 6.1).  
 
Figure A1: Flow cytometry analysis showing the CD133/EpCAM double positive 
population changes upon serum starvation. 
In order to understand the daily shifts occuring in the level of CD133
+
/EpCAM
+
 
population, cells were seeded, and fixed after 24hours, 48 hours and 72 hours after 
seeding. Analyzed by flow cytometry, during first 72 hours, a significant alteration in 
of CD133
+
/EpCAM
+
 fraction could not be observed (Figure 6.2). 
  
108 
 
Figure A2: Flow cytometry analysis showing the CD133/EpCAM double positive 
population changes on a daily basis in complete media. 
The next step to be checked was to shifts in of CD133
+
/EpCAM
+
 population upon 
serum starvation. For this matter, cells were seeded and changed to serum deprived 
media at the end of 72 hours, then cells were collect 24 hours, 48 hours and 72 hours 
after media change. Analysis results did not show a significant alteration in of 
CD133
+
/EpCAM
+
 population upon serum starvation (Figure 6.3). 
The final analysis on Hep3B cell line was on the effects of Notch signaling pathway 
on of CD133
+
/EpCAM
+
 population. For this analysis, cells were seeded and treated 
with Jagged-1 and DAPT in serum starved media, after 72 hours of plantation, then 
cells were collected 72 hours after treatment and analyzed. Analysis results revealed 
that Jagged-1 does not seem to have an effect on of CD133
+
/EpCAM
+
 population, 
but DAPT leads to a drop on the levels of of CD133
+
/EpCAM
+
 population (Figure 
6.4). 
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Figure A3: Flow cytometry analysis showing the CD133/EpCAM double positive 
population changes on a daily basis in complete media vs. serum starved media. 
 
Figure A4: Flow cytometry analysis showing the CD133/EpCAM double positive 
population changes upon Notch signaling alteration. 
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Appendix A2 TLR ligand treatment effects on TLR levels in Hep3B 
In this part, our team aimed for inducing the TLR receptors by using different TLR 
ligands including lipoteichoic acid (LTA), peptidoglycan (PGN), lipopolysaccharide 
(LPS), polyinosinic:polycytidilic acid (Poly(I:C)), flagellin, R848, resiquimod and 
K23. Cells were seeded the day before, and settled overnight, next day, cells were 
induced by different concentrations of TLR ligands, after 4 hours of induction total 
RNA was isolated from the cultured cells. 
Hep3B shows a more induced pattern than Huh7 and HepG2. TLR1 was affected by 
Poly(I:C). TLR4 shown only a very slight banding in response to Poly(I:C), 
Resiquimod and K23. TLR5 showed induction by LTA, Poly(I:C), flagellin, but 
decreased expression by PGN, R848, Resiquimod and K23. TLR6 has given 
expression upon induction by LTA, PGN, Poly(I:C), flagellin, R848 and K23, but 
these responses are very similar to the untreated one. TLR7 was induced by PGN, 
Poly(I:C) and flagellin. TLR10 was also upregulated by Poly(I:C) and flagellin, also 
by K23, but downregulated by R848 and Resiquimod induction Figure 6.5 
 
Figure A5: Gel image showing PCR product bands of TLR levels in Hep3B upon 
treatment with different TLR ligand 
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